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Abstract
Faith A. Strunk, MSN, FNP-BC, AOCNP

Symptoms in Early and Long-Term Breast Cancer Survivors
Who Have Completed Primary Therapy

December 2013
Background:
Many breast cancer survivors continue to have single or multiple symptoms after
they have completed primary cancer therapy. The quantifiable, subjective
experience of multiple symptoms and their impact is defined as symptom burden.
Previous research has focused on symptoms during primary therapy or shortly
after completion.
Objective:
The objectives of this study were to determine whether symptom burden differed
between survivor status (early/long-term) and/or endocrine or hormonal adjuvant
therapy use. We hypothesized that there would be no difference in the symptoms
expressed between early and long-term survivors.
Methods:
In this cross-sectional study, data were collected on 133 survivors, using theM.
D. Anderson Symptom Inventory, Karnofsky Performance Status, Charlson
Comorbidity Index and a demographic/ health history form to assess study
variables.
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Results:
Patients who were prescribed endocrine or hormonal therapy had higher
symptom severity scores than those women who did not receive these therapies.
There were no differences in symptom burden and symptom interference
between early- and long-term survivors, and whether or not they took adjuvant
therapy. As functional status increased , the patients' symptoms scores
decreased. Comorbidities did not impact the symptom scores.

Conclusions: Breast cancer survivors, both early and long-term, continue to
experience symptoms, but those taking hormonal or endocrine therapy
experienced higher symptom severity. Understanding the connections in early
and late survivorship between symptoms, cancer therapy, comorbidities and
functional status may result in improved symptom management and outcomes
for breast cancer survivors.

KeyWords:
Breast cancer, survivor, symptoms, symptom burden, symptom interference,
M.D. Anderson Symptom Inventory (MDASI), Karnofsky Performance Scale
(KPS), Charlson Comorbidity Index (CCI)
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1
Summary of the Study

This dissertation consists of the dissertation proposal which includes the
specific aims, background and significance, research design and methods,
research subject risk and protection, literature cited and appendixes, in the
format of a Public Health Service Grant (PHS 398) and a manuscript entitled
"Symptoms in Early and Long-term Breast Cancer Survivors Who Have
Completed Primary Therapy" which presents the primary findings of the current
research study. The study was approved by the University of Texas M. D.
Anderson Cancer Center Institutional Review Board (IRB) (Appendix A) the
Institutional Review Board at the University of Texas Health Science Center at
Houston and the Committee for the Protection of Human Subjects, (Appendix B,
Appendix C).
The overall objective of this research was to identify and compare the
symptoms experienced by early (less than 3 years post completion of primary
therapy) and long-term (3 through 5 years post completion of primary therapy)
breast cancer survivors based on whether or not they are taking adjuvant
hormonal or endocrine therapy. This study also explored the associations
between functional status, symptom burden and comorbidities as assessed by
the Karnofsky Performance Status (KPS) (Appendix G), theM. D. Anderson
Symptom Inventory (MDASI) (Appendix F), and the Charlson Comorbidity Index
(CCI) (Appendix H).
The study was conducted in the Nellie B. Connally Breast Center at the
University of Texas M. D. Anderson Cancer Center. One hundred thirty four
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participants were recruited, signed informed consent, and completed the study
forms; one later withdrew consent.
Descriptive statistics were used to assess the distributional characteristics
and demographics across survivor status and hormonal therapy use. Symptom
burden and interference were calculated . Chi-square, Fisher's exact test and ttest were conducted to evaluate whether the characteristics differed by survivor
status or use of adjuvant hormonal or endocrine therapy. A 2-way ANOVA was
conducted to evaluate differences in symptom burden, symptom interference and
burden/interference of individual symptoms.
Eligible patients were identified from daily reviews of 28 clinicians' clinic
schedules and were scheduled on the research recruitment schedule (Appendix
K). To facilitate the recruitment process the following techniques were used:
visiting all clinicians that had eligible patients at the start of each clinic day and
alerting them which specific patients at which times were eligible for the study,
then revisiting several times during the day to provide a reminder. In addition,
each clinician's clinic nurse was notified of the potential participant(s) and
requested to let the investigator know when this patient was seen. To address
the space constraint issues, the investigator arrived before clinic hours started, to
request a room in which to administer the questionnaires, as the clinicians were
concerned with maintaining patient schedules.
In order to track time from primary treatment, receipt of endocrine or
hormonal therapy, and stage of disease to ensure equitable distribution of
participant population, the investigator developed a subject log by stage form
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(Appendix J). Patients were stratified by months post treatment; 0-36 months and
37-60 months, for clarity, rather than less than 3 years and 3-6 years.
A minor change to the protocol procedure was made for clarification of
completion of the demographic history form , allowing the investigator or
participant to complete it rather than participant only.
An additional three participants were planned to be recruited because two
recruited earlier were actually early rather than long-term survivors and one
participant withdrew consent after completing the forms. All but one planned type
of participant was recruited ; the investigator was unable to recruit one stage Ill,
long-term survivor not on adjuvant hormonal or endocrine therapy. A total of 134
participants were recruited and the data from 133 analyzed .
The primary findings of the research study are presented in the
manuscript "Symptoms in Early and Long-term Breast Cancer Survivors Who
Have Completed Primary Therapy" (Manuscript A). Demographic and clinical
characteristics were well balanced between survivor status and adjuvant therapy,
by design. There was no difference in symptoms between early and long-term
survivors, although those on adjuvant hormonal or endocrine therapy had higher
symptom severity.
The appendixes A-P contain the following materials: theM. D. Anderson
Institutional Review Board Approval letter, the UT Centralized IRB Review form,
The Committee for the Protection of Human Subjects, the Institutional Review
Board at the University ofTexas Health Science Center confirmation letter for
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agreement to rely on MDACC reviewing IRB, the letter of support from the
Department of Breast Medical Oncology chairman, the demographic data
collection form, theM. D. Anderson Symptom Inventory, the Karnofsky
Performance Status, the Charlson Comorbidity Index, the documents developed
and used in the collection of data, (subject log, subject log by stage, recruitment
schedule), certificate of human subjects protection training, permission to use the
Charlson Comorbidity Index, permission to use the MDASI, theM. D. Anderson
Cancer Center study protocol, and the curriculum vitae.
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Proposal
Significant Aims
Breast cancer is the most common cancer in women in the United States,
with approximately 2 .9 million survivors as of February 2013 (American Cancer
Society, 2013). Usual treatment for women with invasive breast cancer includes
chemotherapy and/or biotherapy, surgery, and/or radiation followed by adjuvant
hormonal therapy, if hormone receptor positive disease.
The cancer and/or its treatment often cause multiple symptoms in
survivors. These symptoms may also be related to other noncancer comorbidities,
noncancer related medications or even other symptoms (Barsevick, Dudley, Beck,
& Whitmer, 2005; Honea, Brant, & Beck, 2007; Kenefick, 2006). Symptoms may
persist and can lead to reducing the dose or discontinuing treatment early which
may affect long term survival (Bonadonna et al. , 2005; Bonadonna, Valagussa ,
Moliternia, Zambetti, & Brambilla, 1995; Cleeland, 2007). Persistent symptoms
also affect the survivors' quality of life.
Understanding the connections between symptoms, cancer therapy,
comorbidities and functional status may result in improved symptom management
and outcomes for breast cancer survivors. This study will evaluate the impact of
functional status, cancer therapy, and comorbidities on the symptoms expressed
in early (up to 3 years) and long- term (years 3 through 5) breast cancer survivors,
who have completed primary therapy (surgery, chemotherapy or biotherapy, with
or without radiation) and compare the symptoms between those taking hormonal
therapy and those not taking hormonal therapy.
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Historically, the literature has addressed the survivors' symptoms during
their primary therapy or shortly thereafter. But no studies have identified and
compared the symptoms experienced by early and longer term breast cancer
survivors based on whether or not they are taking adjuvant hormonal therapy.
This study will identify symptoms that continue to be a problem in survivors who
have completed primary therapy. This proposed study is significant because
establishing this baseline will help to develop and pilot interventions that can be
tested and used effectively in this population .
Primary objectives.
1.

To determine whether symptom burden differs between early
survivors (less than 3 years post-primary therapy) and longterm survivors (3 to less than 6 years post-therapy,
inclusive) .

2.

To determine whether symptom burden differs between
women who take endocrine or hormonal adjuvant therapy
and those who do not.

Secondary objectives.
1.

To determine, whether the effect of time post-treatment and
endocrine or hormonal adjuvant therapy has an additive
effect upon symptom burden or whether it has a synergistic
or antagonistic effect upon symptom burden.

2.

To determine whether symptom interference differs between
early survivors and long-term survivors and between those
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who do and do not take adjuvant endocrine or hormonal
therapy, as well as to determine if time post-treatment and
use of adjuvant endocrine or hormonal therapy have an
additive or interactive effect upon symptom interference.
3.

To determine if differences in individual symptom severity
and interference exist between early and long-term
survivors, with and without the use of adjuvant endocrine or
hormonal therapy.

Exploratory objective.
To determine whether functional status and comorbidities
affect symptom severity and interference.

Background and Significance
Breast cancer is the most common cancer in women in the United States
(excluding skin cancer); 1 in 8 women will develop it during her lifetime
(American Cancer Society, 2013). Overall women treated for breast cancer have
an 89% survival rate after 5 years and 75% after 15 years with an estimated 2.9
million breast cancer survivors in the United States as of February 2013
(American Cancer Society, 2013). The number of all cancer survivors is
projected to grow by 3% per year (Maddams et al. , 2009). The breast cancer
population is no exception; due to improvements in cancer care, earlier diagnosis
and treatment larger numbers of women are living longer and cancer-free after
diagnosis and treatment. Many survivors, once having completed primary
therapy (surgery, chemotherapy/biotherapy, and/or radiation) continue to have
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long-lasting symptoms, single or multiple (Barsevick, 2007; Cleeland, 2007; Janz
et al. , 2007; Rosedale & Fu , 2010). The experience of multiple symptoms has
been identified as symptom burden (Burkett & Cleeland, 2007; Gapstur, 2007;
Gill, Chakraborty & Selby, 2012). Symptom burden is defined as the subjective,
quantifiable prevalence, frequency and severity of symptoms and encompasses
the patient's perception of the impact of symptoms (Cieeland , 2007; Gapstur,
2007).
The experience of symptoms in survivors has been evaluated , but much of
the literature has been focused on symptoms and supportive care during primary
therapy (Chung, Cimprich, Janz, & Mills-Wisneski , 2009). Some studies have
concentrated on the early survivorship periods; beginning at the end of primary
therapy up until 27 months after completing primary therapy (Brant et al. , 2011 ;
Ganz, Kwan , Stanton, Bower, & Belin, 2011 ; Janz et al. , 2007; Park, Bae, Jung,
& Kim, 2011 ; Penttinen et al. , 201 0; Thompson, 2007; Yi, Swartz & ReyesGibby, 2011 ). These studies have found symptoms related to primary therapy
with an impaired quality of life related to these reported symptoms (Bower, 2009;
Dahl, Nesvold , Reinertsen, & Fossa, 2011; Janz et al. , 2007; Park et al. , 2011).
The symptoms most frequently cited in the aforementioned studies included pain,
fatigue or lack of energy, difficulty sleeping, arm pain and lymphedema, breast
symptoms, feeling irritable or nervous, menopausal symptoms, weight changes,
nausea, depression, and cognitive dysfunction. A number of studies have
focused on a specific symptom, such as pain (Lundstedt et al. , 2012; Mao et al. ,
2009; Rief, Bardwell, & Dimsdaile, 2011 ) , lymphedema (Armer & Stewart, 201 0;
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Meeske et al. , 2009; Smoot et al., 201 0), fatigue (Bower et al, 2008; Bower,
Ganz, Irwin, Arevalo, & Cole, 2011; Thompson , 2007) or menopausal symptoms
(Leining et al., 2006; Loibl, Lintermans, Dieudonne, & Neven , 2011 ; Ruddy et al.,
2011). Cancer related fatigue was identified by 21% of both the 1-5 year and 510 year survivors (Bower et al. , 2008). Sleep disturbances, fatigue and pain
persisted in Hartl et al.'s (2003) study of survivors evaluated at an average of 4 .2
years.
Several studies have had contradictory findings. Castellon et al. (2004)
found that cognitive dysfunction symptomatically abated in the 12-24 months
after adjuvant chemotherapy. Jim et al. (2009) found significant differences in
cognitive functioning and cognitive impairment between women who had
received chemotherapy or radiation compared to healthy matched controls after
6 months. In a 2004 review, Tannock, Ahles , Ganz and van Dann found durable
cognitive effects in 9 to 75% of patients, although the higher percentages were
seen in those evaluated in a closer time frame with chemotherapy. However, in
their study of longer term survivors (5- 15 years), Klein et al. (2011) found an
improvement in all symptoms except cognitive functioning and insomnia. The
discrepancies among the findings may be related to the variability in primary
therapy over time, pre-existing comorbidities or the use of adjuvant endocrine or
hormonal therapy.
The proposed study will address the symptoms experienced by both early
survivors (less than 3 years after completion of primary therapy) and long-term
survivors (years 3-5 after completion of primary therapy). Symptoms may be
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caused by comorbid illnesses or acute injuries, related to the disease itself or
may be caused by treatments, in which case they are called side effects or
toxicities (Cieeland , 2007). The framework of Symptom Burden (Cieeland, 2007;
Gapstur, 2007) is the conceptual framework chosen for this study. Symptom
burden has been described as the subjective counterpart to tumor burden
(Cieeland & Reyes-Gibby, 2002) as well as the sum of the severity and impact of
symptoms (Cieeland , 2007). It affects multiple patient outcomes, including
survival, functional status and quality of life (Gapstur, 2007). Symptom burden is
active, and changes over time, as patients undergo therapy or experience
exacerbations or remissions of their disease (Vig & Pearlman , 2003). In this
framework, symptoms related to therapy often are viewed as complicating post
treatment recovery (Cieeland, 2007; Cleeland & Reyes-Gibby, 2002).
In this study, we will assess functional status, comorbidities and the
experience of symptom burden. This study also will explore the association of
comorbidities and symptoms expressed by early and long-term survivors. The
evaluation of concurrent comorbidities is warranted because comorbidities have
been related to symptom severity (Kurtz, Kurtz, Stommel, Given, & Given , 1999).
This study will also address the associations between functional status and
symptoms related to adjuvant endocrine or hormonal therapy.
Historically, the literature has addressed the symptoms of survivors during
their primary therapy or shortly thereafter. But no studies have identified and
compared the symptoms experienced by early and long-term breast cancer
survivors related to the use of adjuvant endocrine or hormonal therapy.
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Innovation
This study is innovative in that it will identify symptoms that potentially
continue to be a problem for survivors who have completed primary therapy. This
study will compare symptoms experienced among women taking adjuvant
endocrine or hormonal therapy and those not taking endocrine or hormonal
therapy, in early (less than 3 years after completion of primary therapy) and longterm (years 3 through completion of year 5 post primary therapy).

Research Design and Methods
Design.
This study utilized an exploratory cross-sectional study design.

Sample and setting.
The sample for this cross-sectional design study will be drawn from adult
female patients in the Nellie B. Connally Breast Center at the University of Texas
M. D. Anderson Cancer Center, an academic, comprehensive cancer center. M.
D. Anderson is the largest institution in the University of Texas system, with 631
inpatient beds and 1,281,489 outpatient visits in 2012. The Nellie B. Connally
Breast Center served over 4,720 new patients and consultations with over 33,000
follow-up visits in 2012. Non-English speaking women will be recruited through
appropriate translation with the assistance of the language assistance office.
Potential participants will be approached at the time of their scheduled routine
clinic visit after approval by their clinic physician. One hundred twenty eight
participants will be recruited ; 64 for each arm.
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Study participants must be an adult female survivor of invasive breast cancer,
without clinical evidence of disease and have completed primary therapy (surgery,
chemotherapy/biotherapy, and radiation). She may be continuing adjuvant
hormonal therapy. She may be non-English speaking. Participants may not be
diagnosed with noninvasive, metastatic, inflammatory, or recurrent breast cancer
and may not be currently receiving chemotherapy or biotherapy. We plan to enroll
33 early survivors who have not received adjuvant endocrine or hormonal therapy,
33 early survivors who have received (or are currently receiving) adjuvant
endocrine or hormonal therapy, 33 long-term survivors who have not received
adjuvant endocrine or hormonal therapy, and 33 long-term survivors who have
received (or are currently receiving) adjuvant endocrine or hormonal therapy. We
will stratify the participants by stage so that 1/3 of each group will have had Stage
I cancer, 1/3 will have had Stage II cancer and 1/3 will have had Stage Ill cancer.
We expect that approximately 80% of breast cancer patients will have used
adjuvant endocrine or hormonal therapy, and that the pool of early-term survivors
will be larger than the pool of late-term survivors.

Instruments.
M. D. Anderson Symptom Inventory (MDASI) . The MDASI is "a
brief measure of the severity and impact of cancer- related symptoms"
(Cieeland et al. , 2000, p.1634) over the previous 24 hours and is
completed by the breast cancer survivor. It contains 13 core symptoms:
fatigue, sleep disturbance, pain , drowsiness, poor appetite, nausea,
vom iting shortness of breath, numbness, difficulty remembering, dry mouth,
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distress and sadness using a 0 (not present)-10 (as bad as you can
imagine) numerical rating scale. Six additional items describe how much
the symptoms have interfered with the patient's life during the past 24
hours using a 0 (did not interfere)- 10 (interfered completely) numerical
scale: general activity, mood , work (including work around the house},
relations with other people, walking and enjoyment of life. The patient
completes the MDASI over 5-7 minutes. The MDASI has demonstrated
internal consistency (reliability) with a coefficient alpha of 0.82 and validity
established with factor analysis in many different studies (Paice, 2004).
The MDASI has been psychometrically and linguistically validated in nine
languages and linguistically validated in another 14 in addition to English .
The MDASI will be used to evaluate symptoms over the previous week,
rather than 24 hours. (Appendix F)

Karnofsky Performance Status (KPS). The KPS is a cliniciancompleted scale. It allows patients to be classified based on their degree of
functional impairment, with a scale from 0 (dead) to 100 (normal, no
complaints, no evidence of disease) (Schag, Heinrich, & Ganz, 1984). It is
further subgrouped into three groups:
A. Able to carry on normal activity and to work no special care is needed
(80-1 00),
B. Unable to work. Able to live at home, care for most personal needs. A
varying degree of assistance is needed (50-70)
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C. Unable to care for self. Requires equivalence of institutional or hospital
care. Disease may be progressing rapidly (0 to 40).
In this study, the KPS will measure functional status. The KPS has shown
reliability and validity previously with Cronbach's alpha of .97 and construct
validity demonstrated with a p<0.001 (Mor, Laliberte, Morris, & W iemann,
1984; Schag et al., 1984.) (Appendix G).

The Charlson Comorbidity Index (CCI) . The CCI will measure
comorbidities. The CCI is an investigator completed index that measures
17 clinical conditions that are weighted to assess the effect of the
conditions on the patient's prognosis (Charlson, Pompei, Ales, &
MacKenzie, 1987). Item scores range from 1 to 6 for each item and are
based on the relative risk for each. Scores range from 0 to 34, with higher
scores signifying greater comorbidity. An adjustment will be made to
address all participants beginning with a score of 2, given because they all
have cancer. It has established reliability with clinical conditions, including
cancer (Hall, Ramachandran , Narayan, Jani, & Vijayakumar, 2004)
(Appendix H).

Demographic/health history questionnaire. The demographic
questionnaire includes age, educational status, race/ethnicity, primary
language spoken, menstrual status (premenopausal- still having periods,
perimenopausal- usual pattern of periods is altered , and postmenopausalno periods for one year or more), work status (employed or not), co-
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morbidities (Have you been diagnosed by a health care provider with any
chronic medical condition- if so please list. If yes, has this cond ition limited
your current daily activities?) (Appendix E). Treatment history was obtained
from the medical record by the investigator (date and type of surgery
(segmental mastectomy vs. mastectomy), type of lymph node surgery if
any,(sentinel node biopsy or axillary node dissection),
chemotherapy/biotherapy (anthracycline, taxane, non-anthracycline and/or
trastuzumab), radiation , and adjuvant hormonal treatments (tamoxifen,
toremifene or aromatase inhibitors).

Data Collection Proced ures.
Study participants will be identified , consented and enrolled at the time of
routine follow-up outpatient clinic visit to the Nellie B. Connally Breast Center. The
health history/demographic questionnaire and the MDASI will be completed by the
participant once enrolled . Data collection will take approximately 10 - 15 minutes.
The principal investigator will determine the Karnofsky score and review the
treatment history from the electronic medical record.

Analysis.
Assuming that 64 patients are enrolled in each arm, we will have 80%
power to detect a difference of medium effect size equivalent to half a standard
deviation in a 5% significance test for acceptable levels of type one and type two
error. Descriptive statistics will be used to assess the distributional
characteristics and demographics across survivor status and hormonal therapy
use. Symptom burden and interference will be calculated separately, as
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recommended by the MDASI User Guide. Chi-squared , Fisher's exact test and ttest will be conducted to evaluate whether the characteristics differed by survivor
status or use of adjuvant hormonal or endocrine therapy. A 2-way ANOVA will be
conducted to evaluate differences in symptom burden, symptom interference and
burden/interference of individual symptoms. Finally, we will add Karnofsky
Performance Status and the Charlson Comorbidity Index to our models to
evaluate impact of functional status and comorbidities upon symptoms. All
models will contain terms for stage of disease to account for stratification on that
factor, as well as a term for age to adjust for the effects of age upon symptom
severity and interference.

Limitations.
There are several potential limitations. Participants will be recruited from
the Nellie B. Connally Breast Center, while there for a routine visit, and therefore
will not be randomly selected . Inclusion will be dependent on the participants'
willingness to participate. Previous studies in this facility have been conducted
with primarily Caucasian, middle class, well-educated participants and may not be
generalizable to minorities or other groups. Because this study is performed at
one Cancer Center, the results may not be generalizable to other patients in other
centers.
A pilot study will precede the planned dissertation research study and will
allow the researcher to identify study limitations and problems, in order to address
them. Even with these possible limitations, this study will provide new information
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about symptoms that will be used to design later longitudinal and intervention
studies.

Alternative Approach.
An alternative approach to studying the identified variables would be a
prospective longitudinal study, The use of a cross-sectional design was chosen
because of the need to gather preliminary data; a later longitudinal cohort study is
planned to evaluate the symptoms in a cohort beginning at 1 year post diagnosis
through 5 years, to evaluate which symptoms persist throughout the 5 years.

Protection of Human Subjects
All consenting members of the research team will undergo institutional
review board training as required by the University of Texas M. D. Anderson
Cancer Center including a 4 hour institutional course and a 1-hour electronic IRB
review module required by the University of Texas MD Anderson Cancer Center
The Institutional Review Board at The University of Texas MD Anderson Cancer
Center will review and approve all consenting materials, including the attached
draft of the informed consent template, prior to use in consenting study
participants. Reciprocal approval will be obtained from the University of Texas
Health Science Center at Houston Committee for the Protection of Human
Subjects
Potential study subjects will be consented at the time of the routine follow
up visit. Risks associated with participation in the study will be outlined in the
informed consent and reviewed with potential subjects by the consenting member
of the research team. Potential participants will be reassured that non-
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participation will not impact their care. Potential risks of study participation are
minimal as the study will consist of completion of questionnaires and data
collection from the medical record.
Consent documents, in addition to study data will be maintained in a locked
file in the Principal Investigator's office and any electronic templates will be
password protected on an institutional computer. Finally, continual oversight for
the ethical procedures of the proposed study will be provided by the institutional
IRB in the form of spontaneous auditing of consenting and data collection
materials.

Women and Minorities Inclusion
All female adult breast cancer survivors attending a follow up visit to the
Nellie B. Connally Breast Center will be approached to participate in this study.
The racial composition of this patient cohort includes individuals of predominantly
Caucasian, middle eastern and Hispanic descent. Non-English speaking
survivors will be approached through the use of a translator in order to broaden
the inclusion of minorities. Women and minority patients are recipients of breast
cancer treatment and as such will be invited to participate in the study and
included to the degree which they consent to participate.
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Abstract
Background

Many breast cancer survivors continue to have single or multiple symptoms after
they have completed primary cancer therapy. The quantifiable, subjective
experience of multiple symptoms and their impact is defined as symptom burden.
Previous research has focused on symptoms during primary therapy or shortly
after completion of treatment.

Objectives

Our study objectives were to determine whether symptom burden differed
according to survivor status (early as opposed to long-term survival) and/or use
of endocrine or hormonal adjuvant therapy. We hypothesized that there would be
no difference in the symptoms expressed among early- and long-term survivors.

Methods

In this cross-sectional study, data were collected on 133 survivors, using the MD
Anderson Symptom Inventory, Karnofsky Performance Status, Charlson
Comorbidity Index and a demographic/health history form to assess study
variables.

Results

Patients who were prescribed endocrine or hormonal therapy had higher
symptom severity scores than did women who did not receive these therapies.
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No differences were noted in symptom burden and symptom interference
between early- and long-term survivors or whether or not they had taken
adjuvant therapy. As functional status increased , the patients' symptoms scores
decreased. Comorbidities did not impact the symptom scores.

Conclusions

Breast cancer survivors continue to experience symptoms, but symptoms are
more severe among those taking hormonal or endocrine therapy. Understanding
the relationship between symptoms, cancer therapy, comorb idities, and
functional status in early versus late survivorship may improve symptom
management and outcomes for breast cancer survivors.

KeyWords

Breast cancer, survivor, symptoms, symptom interference, M. D. Anderson
Symptom Inventory (MDASI), Karnofsky Performance Status (KPS), Charlson
Comorbidity Index (CCI)
Breast cancer is the most common cancer (excluding skin cancer) among
women in the United States; one in eight women will develop the disease
(American Cancer Society, 201 3). Overall, women treated for breast cancer have
an 89% survival rate after 5 years and a 75% survival rate after 15 years
(American Cancer Society, 2013). In 2006, the number of breast cancer
survivors was estimated to be 2.6 million. By 2009 they numbered 2.7 million and
as of 2012 there are over 2.9 million (American Cancer Society, 2013; National
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Cancer Institute, 2012). Earlier diagnosis and treatment and improvements in
cancer care have enabled more women with breast cancer to live longer lives
and , for many, cancer-free.
Many survivors who have completed their primary treatment (surgery,
chemotherapy/biotherapy, and/or radiation therapy) may continue taking hormonal
therapy. Once primary treatment is over, survivors expect their symptoms to
subside. Unfortunately many breast cancer survivors continue to have long-lasting
symptoms related to their cancer and/or its treatment (Barsevick, 2007; Cleeland,
2007; Janz et al., 2007; Rosedale and Fu, 2010).
Multiple symptoms that persist are known as symptom burden (Burkett and
Cleeland , 2007; Gapstur, 2007; Gill, Chakraborty, and Selby, 2012). Symptom
burden is the subjective, quantifiable prevalence, frequency, and severity of
symptoms and encompasses the patient's perception of the symptoms' impact
(Cieeland, 2007; Gapstur, 2007).
Symptom burden has been evaluated, but much of the research has
focused on symptoms and supportive care during primary therapy (Chung,
Cimprich, Janz, and Mills-Wisnesky, 2009). However, several studies have
concentrated on the early survivorship periods--beginning and continuing
through the first 27 months following completion of primary therapy (Brant et al. ,
2011; Ganz, Kwan, Stanton , Bower, and Belin , 2011 ; Janz et al. , 2007; Park,
Bae, Jung, and Kim , 2011 ; Penttinen et al. , 20 10; Thompson, 2007; Yi, Swartz
and Reyes-Gibby, 2011 ). Findings suggest that symptoms related to primary
therapy contribute to impaired quality of life (Bower, 2009; Dahl, Nesvold ,
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Reinertsen , and Fossa, 2011; Janz et al., 2007; Park et al., 2011 ). The
symptoms most frequently cited in the aforementioned studies include pain,
fatigue or lack of energy, difficulty sleeping , arm pain and lymphedema, breast
symptoms, feeling irritable or nervous, menopausal symptoms, weight changes,
nausea, depression , and cognitive dysfunction.
A number of studies have focused on a specific symptom, such as pain
(Lundstedt et al. , 2012; Mao et al. , 2009; Rief, Bardwell, and Dimsdaile, 2011),
lymphedema (Armer and Stewart, 2010; Meeske et al. , 2009; Smoot et al. ,
2010), fatigue (Bower et al. , 2008; Bower, Ganz, Irwin , Arevalo, and Cole, 2011 ;
Thompson, 2007) or menopausal symptoms (Leining et al. , 2006; Loibl,
Lintermans, Dieudonne, and Neven, 2011 ; Ruddy et al. , 2011 ). Other studies
have explored longer-term issues. For example, the incidence of lymphedema
was found to persist and/or increase over five years (Armer and Stewart, 201 0;
Norman et al., 2009). Cancer-related fatigue was cited by 21 % of both the 1- to
5-year survivors and the 5- to 10-year survivors (Bower et al. , 2008). Sleep
disturbances, fatigue, and pain had persisted in survivors evaluated at an
average of 4.2 years (Hartl et al. , 2003).
Several studies have yielded contradictory findings . For example, the
results of one study suggested that cognitive dysfunction abated in the 12 to 24
months after adjuvant chemotherapy (Castellon et al. , 2004). Jim et al. (2009),
however, found significant differences in cognitive functioning and cognitive
impairment after six months among women who had received chemotherapy or
radiation therapy compared to healthy matched controls. Tannock et al.'s 2004
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review found durable cognitive effects in 9 to 75% of patients, although the
higher percentages were observed among those evaluated closer to completion
of chemotherapy. However, in a study of longer-term survivors (5 to 15 years),
Klein et al. (2011) found an improvement in all symptoms except cognitive
functioning and insomnia. The discrepancies among these findings may be
attributable to variability in primary therapy over time, pre-existing comorbidities,
or use of adjuvant endocrine or hormonal therapy.
The likelihood of poor health was much higher among those who had
another comorbid condition (Elliott et al. , 2011). Other studies have excluded
participants who had an additional significant chronic illness (Thompson, 2007).
Functional status has been addressed in previous studies and low functional
status is associated with poorer quality of life (Penttinen et al. , 201 0).
Symptoms may arise from comorbid illnesses or acute injuries related to
the disease itself, or they may be attributable to cancer treatment and manifested
in the form of side effects or toxicities (Cieeland, 2007). Symptom burden
(Cieeland , 2007; Gapstur, 2007) is the conceptual framework chosen for this
study. Symptom burden has been described as the subjective counterpart to
tumor burden (Cieeland and Reyes-Gibby, 2002) and as the sum of the severity
and impact of symptoms (Cieeland , 2007). Symptom burden affects multiple
patient outcomes, including survival, functional status, and quality of life
(Gapstur, 2007). Symptom burden is active and changes over time as patients
undergo treatment or experience exacerbations or remissions of their disease
(Vig and Pearlman, 2003). In this framework, symptoms related to treatment
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often are viewed as complicating post-treatment recovery (Cieeland , 2007;
Cleeland and Reyes-Gibby, 2002).
Historically, the symptoms of survivors during primary therapy or shortly
thereafter have been addressed in the literature. But no studies have identified
and compared the symptoms related to the use of adjuvant endocrine or
hormonal therapy that are experienced by early- and long-term breast cancer
survivors.
The primary objective of this study was to determine whether symptom
burden differed by survivor status (early versus long-term) and/or the use of
endocrine or hormonal therapy. We hypothesized that no difference would be
seen in the symptoms expressed among early- and long-term survivors.

This study also explored the association of comorbidities and symptoms
expressed by early- and long-term survivors. Evaluation of concurrent
comorbidities was warranted because comorbidities have been associated with
symptom severity (Kurtz, Kurtz, Stommel et al.1999). This study also addressed
the associations between functional status and symptoms related to adjuvant
endocrine or hormonal therapy.

Materials and Methods
Study design
The study design was exploratory and cross-sectional. Institutional Review
Board approval was obtained, and all subjects provided informed consent.
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Setting

The study was conducted at the Nellie B. Connally Breast Center at The
University of Texas MD Anderson Cancer Center, an academic, comprehensive
cancer center. MD Anderson is the largest institution in The University of Texas
system, with 631 inpatient beds and 1,281 ,489 outpatient visits in 2012. The
Nellie B. Connally Breast Center served more than 4, 720 new patients and
consultation visits, and conducted more than 33,000 follow-up visits in 2012.

Study Participants

The participants were adult women who had completed primary treatment
for breast cancer (surgery, chemotherapy/biotherapy, and/or radiation) as many
as six years earlier and were receiving follow-up care at the Breast Center. NonEnglish speaking women were recruited with the assistance of the MD
Anderson's Language Assistance office. Exclusion criteria included diagnosis of
non-invasive, metastatic, inflammatory, or recurrent breast cancer or current
active treatment with chemotherapy or biotherapy. Participants could be taking
adjuvant hormonal or endocrine therapy. The patients were consecutively
recruited as they presented to the Breast Center for a routine follow-up visit and
were stratified by time (early: 0 to 36 months after primary treatment versus longterm : 37 to 60 months after primary treatment), disease stage (1, II, or Ill), and
whether or not they were taking adjuvant hormonal or endocrine therapy.
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Sample Size

Using a 2 x 2 factor analysis model, with 33 survivors per cell (long/shortterm survival by adjuvant endocrine therapy) , we had 80% power to detect a oneunit difference in mean symptom burden scores through the use of adjuvant
endocrine therapy. This translates into a standard deviation among means of
0.5. We also had more than 95% power to detect a two-unit difference between
early- and long-term survivors-the same as a 1.0 standard deviation among
means-and to detect a 1.12 standard deviation among means for the interaction
effect. All testing was 2-sided, using a 5% level of statistical significance. A
subject standard deviation of 2.0 was used to calculate power, based upon
findings by Cleeland (2007). Because we had two primary objectives (the main
effect of short/long-term survival and the effect of adjuvant endocrine/hormonal
therapy), we had a 10% chance of falsely rejecting at least one of our primary
hypotheses.
Data Collection Procedures

Study participants were identified , gave their informed consent, and were
enrolled during their routine follow-up outpatient clinic visit to the Breast Center.
Once enrolled, each participant completed the MD Anderson Symptom Inventory
(MDASI). The principal investigator determined each patient's Karnofsky score,
completed the demographic and health history questionnaire with the participant,
and extracted the treatment history from the electronic medical record.
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Instruments
Demographic/health history questionnaire. The demographic/health
history questionnaire includes age, educational status, race/ethnicity, primary
language spoken, menstrual status, work status, comorbidities, treatment history,
and use of any adjuvant hormonal therapy.

MD Anderson Symptom Inventory (MDASI). The MDASI was used to
measure symptom severity, interference, and burden. The MDASI is a 19-item
self-report measure of the severity and impact of cancer-related symptoms
(Cieeland et al, 2000). It addresses 13 core symptoms: fatigue, sleep
disturbance, pain, drowsiness, poor appetite, nausea, vomiting , shortness of
breath, numbness, difficulty remembering, dry mouth, distress, and sadness
using a numerical rating scale of 0 (not present) to 10 (as bad as you can
imagine). Six additional items address how much the symptoms have interfered
with the patient's life during the past 24 hours, using a numerical scale of 0 (did
not interfere) to 10 (interfered completely) regarding general activity, mood, work
(including work around the house), relations with other people, walking, and
enjoyment of life. Symptoms may be categorized as 0-4 mild, 5-6 moderate, and
7 or above severe; ratings of 5 or higher indicate a moderate-to-severe symptom
that significantly impairs daily function ing (Mendoza et al. , 2013). The MDASI
takes approximately 5 to 7 minutes to complete. The inventory has demonstrated
internal consistency (reliability) with a coefficient alpha of 0.82, and its validity
has been established with factor analysis (Paice, 2004) in many different studies.
The MDASI has been psychometrically and linguistically val idated in nine

34
languages and linguistically validated in another 14 languages in addition to
English. The MDASI was used to evaluate symptoms over the previous week,
rather than 24 hours. Internal consistency of the MDASI for this study was
measured by Cronbach's alpha= 0.91.

Charlson Comorbidity Index (CCI). The CCI was used to measure
comorbidities. The CCI is an investigator-completed index that measures 17
clinical conditions that are weighted to assess the effect of the conditions on the
patient's prognosis (Charlson, Pompei, Ales, and MacKenzie, 1987). Item scores
range from 1 to 6 for each item and are based on the relative risk for each.
Scores range from 0 to 34, with higher scores signifying greater comorbidity. One
of the ten comorbidity items on the CCI is cancer, thus each subject began with a
score of two. The CCI has an established reliability with clinical conditions,
including cancer (Hall, Ramachandran, Narayan, Jani, and Vijayakumar, 2004).

Karnofsky Performance Status (KPS). Patients' functional status was
measured with the Karnofsky Performance Status. The KPS is a clinician- or
investigator-completed scale that classifies patients according to their degree of
functional impairment on a scale from 0 (deceased) to 100 (normal, no
complaints, no evidence of disease) (Schag, Heinrich, and Ganz, 1984). The
KPS is further divided into three subgroups: A) Able to carry on normal activity
and to work, with no special care needed (80-100), B) unable to work, able to live
at home and care for most personal needs, varying amounts of assistance
needed (50-70), and C) Unable to care for self, requires equivalent of institutional
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or hospital care; disease may be progressing rapidly (0-40). The KPS has shown
reliability and validity previously with a Cronbach's alpha of 0.97 and construct
validity demonstrated with a p<0.001 (Mor, Laliberte, Morris, and Wiemann,
1984; Schag et al., 1984).

Statistical Analysis
The objectives of this study were to determine whether symptom burden
differed between survivor status (early/long-term) and/or endocrine or hormonal
adjuvant therapy use. Early survivors were defined as those who had finished
primary treatment fewer than three years or 36 months prior to the date of the
survey. Long-term survivors were defined as those who had finished their
primary treatment at least three years, but less than six years (37 to 60 months),
before the date of the survey.
Descriptive statistics were used to assess the distributional characteristics
and demographics of the study population across survivor status and use of
hormonal therapy. Chi-squared, Fisher's exact test, and t-test were conducted to
determine whether these characteristics differed by survivor status as well as by
the presence or absence of current adjuvant endocrine or hormonal therapy.
Symptom burden and interference were calculated separately according to the
prorated score recommended by theM . D. Anderson Symptom Inventory User
Guide.
A two-way ANOVA model was conducted to evaluate differences in
symptom burden, symptom interference, and burden/interference of individual
symptoms. We conducted another set of ANOVA models with the KPS and the
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Charlson Comorbidity Index (CCI) to evaluate the impact of functional status and
comorbidities on symptoms. A third two-way ANOVA model was used to
evaluate differences in the individual MDASI items by survivor status and
hormone therapy treatment. All models contain terms for stage to account for
stratification on that factor, as well as age for the effects of age upon symptom
severity and interference. The interaction between the two factors was tested in
all models but was dropped if the term was non-significant. Cronbach's alpha
was used to measure the internal consistency of MDASI with severity (a= 0.84),
interference (a= 0.88), and overall MDASI (a= 0.91).

Results
A total of 141 patients were sequentially approached to participate in the
study over a period of four months; 134 agreed to participate. Individuals who
chose not to participate did so primarily because of time constraints. One
individual withdrew her consent, leaving 133 study participants.

Patients and Disease Demographics

Patient characteristics, both demographic and disease-related, were well
balanced between survival status and use of adjuvant therapy (Table 1).
Subjects were predominantly white, non-Hispanic (65.4%), English-speaking
(89.5%), married (72.7%), had a high school education (30.8%), and were a
mean age of 56 (range, 30.5-83.0) The majority had estrogen receptor- positive
(58.6%), Her2/neu-negative (80.5%) disease. Disease stage was stratified by
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design , with equal numbers of stage I, II, and Ill in both arms (early and longterm). The majority had received chemotherapy (74.2% taxane, 68.3%
anthracycline, and 9.8% other), but only 19.5% received trastuzumab. More
women had undergone modified radical or total mastectomy (56.4%) than
segmental mastectomy (45.9%). About half had undergone sentinel lymph node
biopsy only (48.9%), half (51 .1%) had axillary node dissection, and 78.2% of
participants received adjuvant radiation therapy.

Primary Treatment History
In general, treatment history among early- and long-term survivors was
not statistically significant, except for taxane chemotherapy and adjuvant therapy.
Early survivors were more likely to have been treated with taxanes than were
long-term survivors (82.8% vs. 66.2%; p=0.0289). In addition, women who were
not on adjuvant therapy were more likely to have received primary treatment with
taxanes (87.7% vs. 61.2% ; p=0.0005) . Receipt of anthracycline chemotherapy
did not differ among early- vs. long-term survivors. The type of breast and axillary
surgery was not statistically significant for these groups. Women who received
adjuvant therapy were more likely to have received radiation therapy (p=0.0426).

MDASI Results
Summary statistics for all the MDASI items are shown in Table 2. The
frequency of reported symptoms and their severity/interference are shown in
Table 3. No statistical evidence for a relationship between comorbidities and
MDASI scores was observed ; however, this patient population had few
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comorbidities as indicated by the low CCI scores in general. As the Karnofsky
Performance scores increased, MDASI scores decreased but not significantly,
indicating that individuals with greater performance status had lower symptom
severity.
Symptom frequency and severity
All but five of the women reported experiencing at least one symptom.
Most women (81 .2%) endorsed five or more symptoms. The majority of
symptoms were in the mild to moderate categories, although 44% of women
scored at least one symptom in the severe range (7 or higher). Fatigue was the
most commonly reported symptom, whereas sleep disturbance was rated highest
in severity.
Symptom severity and survivor status
Survivor status did not significantly impact the MDASI scores, and no
significant difference was noted· between early or long-term survivors in relation
to reports of symptom severity. The interaction term between survivor status and
adjuvant endocrine or hormonal therapy use was non-significant in all models,
indicating no differences in symptom burden and interference between early and
long-term survivors, regardless of adjuvant therapy use.

Symptom severity and adjuvant therapy use
Patients who had endocrine or hormonal therapy had higher symptom
severity scores than did the women who did not, as reflected in the MDASI
scores (1-1

=29.1 vs. 1-1 =22.0; p =0.0250)
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Symptom severity and Karnofsky Performance Status

Karnofsky Performance Status was significantly related to pain (p

=

=0.0217), sleep (p =0.0249), distress (p =0.0040),
remembering things (p =0.0292) ,and numbness (p =0.0195), with lower KPS

0.0004), fatigue (p

scores being related to higher symptom severity.

Symptom Severity and Charlson Comorbidity Index

The Charlson Comorbidity Index was significantly related only to symptoms of
nausea (p

=0.0000) and vomiting (p =0.0050).
Discussion

This study sought to examine the occurrence of symptom burden in early
and long-term survivors with or without endocrine or hormonal adjuvant therapy
use. Data suggested few statistically significant relationships between and
among study variables. However, as would be expected for women taking
adjuvant endocrine or hormonal therapy, these survivors had significantly higher
symptom severity scores than did the women who did not receive these
therapies. This finding may be attributable to the side effects of the hormonal or
endocrine adjuvant therapies, including hot flashes , fatigue, insomnia, or
headaches (Bowles, et al., 2012). Pain is another commonly reported symptom
(Dunn & Gotay, 2013). Although clinicians discuss with their patients that the
symptoms related to hormonal or endocrine therapy may improve over time, no
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significant differences are seen in the scores of early versus long-term survivors
who receive these therapies. The assumption was that closer to primary
treatment, the survivor would experience certain symptoms that would resolve
over time, although other symptoms might persist. Therefore, from clinical
experience, we expected that long-term survivors would have fewer symptoms
overall. However, our results suggest that women continue to experience multiple
symptoms after treatment completion. Few studies have evaluated symptoms
five years after diagnosis (Koch et al. , 2013), when routine follow-up care has
ended. This emphasizes the need to continue to assess symptom burden
throughout the cancer treatment trajectory.
The median age of the participants was 56, which is lower than the
median age of 61 for breast cancer diagnosis in the United States (American
Cancer Society, 2013). It is unclear why our participants were younger. It may be
that younger women are referred to our institution more often or that younger
women tend to participate in research studies, but this finding reflects the
literature, which often reveals a younger median age (Bower et al., 2006;
Broeckel, Thors, Jacobsen, Small, and Cox, 2002; Carlson, Campbell, Garland
and Grossman, 2007; Eversley et al., 2005; Otte, Carpenter, Russell, Bigatti,
andChampion, 201 0). The younger age of our patients may affect the symptoms
expressed; as in previous studies, older women tended to minimize and attribute
any symptoms they had to aging (Heidrich, Egan, Hengudomsub, and Randolph,
2006; Reiland and Heidrich, 2011; Royer, Phelan, and Heidrich, 2009)
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Women with more symptoms have poorer functional status, whereas
women with fewer symptoms have higher functional status scores. Our study
bolstered these findings; as the Karnofsky Performance scale increased (nearer
to 100 or normal function) , the MDASI scores decreased (i.e. , fewer symptoms or
lower symptom burden). All study participants had completed primary therapy
and were without evidence of disease, and they all scored at least an 80 on the
KPS scale, which indicates the ability to carry on normal activity and to work.
Multiple studies have noted the most prevalent symptoms in breast cancer
survivors to be pain, fatigue, disturbed sleep, cognitive problems, and mood
(Dodd, Cho, Cooper, and Miaskowski, 201 0). Our study had similar findings
(Table 3), with the top five symptoms reported as fatigue , remembering things,
disturbed sleep, pain, and feeling drowsy, although our study participants
reported mood complaints less often. Vomiting was the least frequently reported
symptom, as would be expected of women who had completed primary therapy.
One unexpected finding was how often these survivors reported dry mouth. Dry
mouth is not a symptom that is often reported as a concern in the clinical setting.
In general, most survivors reported mild to moderate symptoms.
These data suggest persistence of mild to moderate symptom burden
following breast cancer treatment regardless of survivor status. Statistically
significant findings suggesting increased symptom severity for women receiving
adjuvant endocrine or hormonal therapies identify a clinical opportunity to assess
which symptoms develop at what point in time as a means of further addressing
those symptoms and developing interventions. Moreover, for patients who
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require more than the current five years of adjuvant therapy with hormonal or
endocrine agents, this study identifies the need for attentive assessment of
continued symptoms longer into survivorship for this population. Although few
statistically significant relationships were found between and among other study
variables, the impact of adjuvant therapy on female breast cancer patients' posttreatment symptom severity offers valuable insight for clinical practice.

Strengths and Limitations
One of the strengths of this study was the emergence of evidence
indicating that symptom burden persists for women treated for breast cancer in
both an early and long-term survivorship time frame. This finding adds to the
existing literature related to symptom burden during and immediately following
treatment. Moreover, symptom burden may be exacerbated by prolonged
endocrine or hormonal adjuvant therapy. These findings inform clinical practice,
which focuses on evaluating and managing symptom burden throughout
survivorship, even after the completion of primary therapy.

This study had several limitations. Because this was a cross-sectional
study, the duration of the symptoms could not be evaluated . Sampling bias may
have occurred as participants were recruited from the Breast Center while they
were there for a routine visit and therefore were not randomly selected . In
addition, because this study was performed at only one cancer center, the results
may not be generalizable to patients in other centers. Moreover, the majority of
women in this study were married, white, non-Hispanic, employed full-time , high

43
school graduates-demographics that are not reflective of national data and may
not be generalizable to minorities or other groups. Women of other races or
ethnic groups may experience different symptoms. In addition, male breast
cancer survivors were excluded from this study, are underrepresented in the
literature, and may also experience different symptoms.

Research Implications
Although the number of participants who reported severe symptoms was
low, most survivors reported at least one symptom (96%) , and the majority of
survivors in this study reported five or more. The most common, severe, and
distressing symptoms need further evaluation. Longitudinal studies that compare
survivors to healthy women are needed in order to characterize symptom
incidence and persistence over time. Further research should be directed toward
assessing the long-term impact of symptoms and evaluation of symptom
distress. In addition, studies that comprise participants who reflect the age of the
U. S. breast cancer population are needed , as are studies with minority
populations that can provide insight into the symptom experiences of breast
cancer survivors who are minorities.

Clinical Implications
Clinicians who care for breast cancer survivors need to be aware that the
majority of these survivors, whether early or long-term , have symptoms, and that
those who are on adjuvant hormonal or endocrine therapy experience greater
symptom severity. Although most women in this study did not have significant
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distress, assessment of the presence and severity of symptoms should be a
routine part of oncology care. Clinicians can then provide anticipatory guidance
and inform survivors about the persistence of symptoms. This will enable
survivors to anticipate symptoms and will encourage development of programs to
assist survivors in dealing with symptoms more effectively.

Conclusions

We conducted this study to evaluate symptoms experienced by breast
cancer survivors who completed primary therapy. From clinical experience, we
expected symptoms to lessen over time, and surmised that long-term survivors
would have fewer symptoms. Our analysis revealed that both early and long-term
survivors had symptoms, but those taking adjuvant endocrine or hormonal
therapy experienced greater symptom severity, whether early- or long-term.
Establishing this baseline will help to develop pilot interventions that can be
tested and used effectively in this population. Understanding the connections
among symptoms, cancer therapy, comorbidities, and functional status may
result in improved symptom management and outcomes for breast cancer
survivors.
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. /h armona lth erapy
Demograpih 1.cs b>y SUfVIVOr StatUS and en docnne
Survivor Status
Early n = 65)

Adjuvant endocrine or hormonal therapy

Long n = 68)

No (n = 65)

Yes (n = 68)

Total (n = 133)

N

%

N

%

N

%

N

%

N

%

54.7

10.9

57.3

11.4

54.6

10.7

57.5

11.5

56.0

11.2

None

32

49.2

33

48.5

65

100

0

0.0

65

48.9

Anastrazole

13

20.0

18

26.5

0

0.0

31

45.6

31

23.3

Exemestane

0

0.0

1

1.5

0

0.0

1

1.5

1

0.8

Letrozole

8

12.3

4

5.9

0

0.0

12

17.6

12

9.0

Tamoxifen

12

18.5

12

17.6

0

0.0

24

35.3

24

18.0

Negative

26

40.0

29

42.6

54

83.1

1

1.5

55

41.4

Positive

39

60.0

39

57.4

11

16.9

67

98.5

78

58.6

Neqative

32

49.2

31

45.6

56

86.2

7

10.3

63

47.4

Positive

33

50.8

37

54.4

9

13.8

61

89.7

70

52.6

Negative

53

81 .5

54

79.4

47

72.3

60

88.2

107

80.5

Positive

12

18.5

14

20.6

18

27.7

8

11 .8

26

19.5

Divorced

7

10.9

12

17.6

13

20.3

6

8.8

19

14.4

Married/Partnered

47

73.4

49

72.1

41

64.1

55

80.9

96

72.7

Characteristic
Age(Mean)
Medication

ER

PR

Her2

Marital Status

SEJparated

3

4.7

0

0.0

1

1.6

2

2.9

3

2.3

Single, living alone

4

6.3

2

2.9

4

6.3

2

2.9

6

4.5

Sinqle, livinq w/adult

1

1.6

1

1.5

2

3.1

0

0.0

2

1.5

Widowed

2

3.1

4

5.9

3

4.7

3

4.4

6

4.5

Asian/Pacific Islander

2

3.1

0

0.0

0

0.0

2

2.9

2

1.5

Black Non-Hispanic

14

21 .5

10

14.7

12

18.5

12

17.6

24

18.0

Hispanic

8

12.3

11

16.2

8

12.3

11

16.2

19

14.3

Other

1

1.5

0

0.0

1

1.5

0

0.0

1

0.8

White Non-Hispanic

40

61.5

47

69.1

44

67.7

43

63.2

87

65.4

Race

Staqe
I

19

29.2

24

35.3

20

30.8

23

33.8

43

32.3

II

22

33.8

23

33.8

22

33.8

23

33.8

45

33.8

Ill

24

36.9

21

30.9

23

35.4

22

32.4

45

33.8

80

16

24.6

8

11.8

7

10.8

17

25.0

24

18.0

90

23

35.4

34

50.0

27

41.5

30

44.1

57

42.9

100

26

40.0

26

38.2

31

47.7

21

30.9

52

39.1

Karnofsky Performance Status
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Table 1 cont'd :

. (h armona I th erapy
Demograp,h"tcs b'Y survtvor s ta tus an d en docnne
Survivor Status
Early (n
Characteristic

=65)

N

%

Adjuvant endocrine or hormonal therapy

Long (n

=68)

No (n

=65)

N

%

N

%

N

%

N

%

Yes (n

=68)

Total (n

=133)

Charlson Comorbidit" Index
2

51

78.5

48

70.6

51

78.5

48

70.6

99

74.4

3

12

18.5

13

19.1

12

18.5

13

19.1

25

18.8

4

1

1.5

7

10.3

1

1.5

7

10.3

8

6.0

5

0

0.0

0

0.0

1

1.5

0

0.0

1

0.8

No

11

17.2

23

33.8

8

12.3

26

38.8

34

25.8

Yes

53

82.8

45

66.2

57

87.7

41

61 .2

98

74.2

Chemotaxane

Chemoanthracycline
No

16

24.6

26

38.2

13

20.0

29

42.6

42

31 .6

Yes

49

75.4

42

61.8

52

80.0

39

57.4

91

68.4

No

58

89.2

62

91.2

58

89.2

62

91.2

120

90.2

Yes

7

10.8

6

8.8

7

10.8

6

8.8

13

9.8

No

53

81 .5

54

79.4

47

72.3

60

88.2

107

80.5

Yes

12

18.5

14

20.6

18

27.7

8

11 .8

26

19.5

15

23.1

14

20.6

19

29.2

10

14.7

29

21.8

58

85.3

104

78.2

Chemo-other

Trastuzumab

XRT
No
Yes

50

76.9

54

79.4

46

70.8

Segmental mastectomy
No

35

53.8

37

54.4

36

55.4

36

52.9

72

54.1

Yes

30

46.2

31

45.6

29

44.6

32

47.1

61

45.9

MRM or total mastectomy
No

27

41 .5

31

45.6

28

43.1

30

44.1

58

43.6

Yes

38

58.5

37

54.4

37

56.9

38

55.9

75

56.4

No

34

52.3

34

50.0

31

47.7

37

54.4

68

51.1

Yes

31

47.7

34

50.0

34

52.3

31

45.6

65

48.9

No

31

47.7

34

50.0

34

52.3

31

45.6

65

48.9

Yes

34

52.3

34

50.0

31

47.7

37

54.4

68

51.1

SLN only

AND
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Table 2
Summary sta t"1sf1cs nor th e MDASI

Variable
Core s~m12toms
Pain
Fatigue
Nausea
Sleep
Distress
Shortness of breath
Remembering things
Lack of appetite
Drowsy
Dry mouth
Sad
Vomit ing
Numbness
MDASI SEVERITY
Interfer~nce items
General activity
Mood
Work
Relations
Walking
Enjoyment of life
MDASI INTERFERENCE
MDASI
Note. Cronbach's alpha's for

N

Mean

SD

Min

Max

133
132
132
131
133
133
132
133
133
132
133
133
133
133

2.9
3.4
0.5
3.3
2.6
1.0
2.8
0.8
2.4
1.4
2.2
0.1
2.4
25.7

2.8
2.5
1.7
3.0
2.8
1.9
2.7
1.7
2.6
2.1
2.7
0.6
2.8
18.2

0
0
0
0
0
0
0
0
0
0
0
0
0
0

10
10
10
10
10
9
10
9
10
10
10
6
10
92

133
133
133
133
133
133
133
133

2.1
2.0
2.3
0.9
1.9
1.4
10.6
36.2

2.4
2.4
2.7
1.7
2.6
2.1

0
0
0
0
0
0
0
0

10
10
9
7
9
9
42
125

11.1

27.3

Seventy (0.84), Interference (0.88), MDAS I (0.91)
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Table 3
Symptom frequency, Percentage reported moderate/severe and the average symptom
sevemy,m
"t'iitm
e erence score

Variable

N

%

Mean

SD

ModfSev
Core S~mntoms
Pain
Fatigue
Nausea
Sleep
Distress
Shortness of breath
Remembering things
Lack of appetite
Drowsy
Dry mouth
Sad
Vomiting
Numbness
Interference Items
General activity
Mood
Work
Relations
Walking
Enjoyment of life

92
113
17
98
90
44
104
32
92
59
78
4
84

42
39
47
44
33
27
34
25
34
22
36
25
29

4.2
4.0
4.0
4.4
3.8
3.1
3.6
3.2
3.5
3.2
3.7
3.0
3.7

2.4
2.3
2.9
2.7
2.6
2.0
2.5
2.3
2.5
2.0
2.6
2.2
2.6

78
85
81
49
67
60

32
26
37
20
40
28

3.5
3.1
3.7
2.6
3.8
3.1

2.2
2.4
2.5
2.0
2.5
2.2
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Appendix A

M. D. Anderson Institutional Review Board Approval Letter
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THE tJNrvE:ASITY OF

T~XAS

Institutional Review Board (IRB)
Unit 1437
Phone 713-792-2933
Fax 713-794-4589

MD .Anderson

Ganc~Ce11ter
Office of Protocol Research

11/18/2012
Faith A Strunk
Veronica Roberts
Diana L. Urbauer, Geri Wood, LaTonia R. Okadigwe, OPR Protocol Activations
MDACC ProtocoiiD # :
2012-0909
Symptoms in Early and Long-term Breast Cancer Survivors Who
Protocol Title:
Have Completed Primary Therapy
03
Version:
To:
From :
CC:

Subject:

Contingencies Met - Protocol 2012-0909
OfficiaiiRB Approval Date:

11/09/2012

On 11 /14/2012 the Institutional Review Board 4 committee, chair, or designee granted approval
to the above named and numbered protocol since the contingencies outlined by the IRB 4 on
11/09/2012 have been met.
It was noted that the protocol, informed consent documents (ICDs) and/or the Waivers of lCD and
Authorization are satisfactory and in compliance with federal and institutional guidelines. No
participants may be entered on this protocol until it has been officially activated by OPR.
In keeping with the requirements outlined in 45CFR46.109(e) and 21 CFR56.109(f), the IRB shall
conduct continuing review of all protocols at intervals appropriate to the degree of risk, but not
less than once per year.
You are responsible for promptly reporting to the IRB:
any severe adverse events;
any death while patient is on study;
any unanticipated problems involving risks to subjects or others;
any proposed changes in the research activity (changes may not be initiated without IRB
review and approval, except w here necessary to eliminate apparent immediate hazards to
the subjects).

To activate this study, please compose and send a "Request for Activation" memo in POOL.
The existing Informed Consent and/or Waivers of Informed Consent and Authorization cannot be
used until the protocol is Activated.
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If a Material Transfer Agreement (MTA) is required , it must be obtained prior to Activation.

In the event of any questions or concerns, please contact the sender of this message at (713)
792-2933.
Veronica Roberts 11/18/2012 04:23:37 PM

This is a representation of an electronic record that was signed and dated
electronically and this page is the manifestation of the electronic signature
and date:
Veronica Roberts
11/18/2012 04:23:20 PM
IRB 4 Chair Designee
FWA # : 00000363
OHRP IRB Registration Number: IRB 41RB00005015
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Appendix B

UT Centralized IRB Review Form
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UT Centralized IRB Review
Notification to Relying Organization
Intent to Submit for Centralized Review
Information for the Overall Principal Investigator- In addition to submitting an application to your organization's IRB (designated
the "Reviewing IRB'), an "Intent to Submit for Centralized Review" form must be submitted to the IRB office at each participating
organization.
Information for the Site Principal Investigator- The purpose of this form is to request centralized review at your organization
(designated the "Relying Organization"). This request will be considered by your organization and a decision made on a case-by-case
basis. The IRB office from your organization will forward the final decision to the Reviewing IRB.
If your organization agrees to Centralized IRB Review, you will be required to submit additional materials in accordance with local
policy. The review of local issues by your organization is a separate process from the IRB approval being sought by the Overall Pl.
Reminder. you are not authorized to initiate research at your organization until both processes are completed: 1) the study is
approved by the Reviewing IRB and an approval letter is issued, and 2) the local policy issues have been resolved and an activation
letter has been issued by your Organization.

Study Title:

Department:
PI 's Telephone#:
PI's e-mail address:

PI's FAX Number:

flame of the Overall Principal Investigator (PI~:
Overall PI's Name (Last Name, First Name, Ml):
Organization:

I Af\ iJ Atyj<£ !iQo

3. Which University of Texas Participating Organization will serve as the Reviewing IRB?
Select only one

-

-

UT at Arlington (UTA)

UT Pan American

UT Medical Branch (UTMB)

UT Austin (UT Austin)

UT Permian Basin

UT HSC at Houston (UTHealth)

UT Brownsville

UT San Antonio (UTSA)

UT HSC at San Antonio (UTHSCSA)

UT at Dallas (UTD)

UT Tyler

UT Health Science Center Tyler

UT at El Paso (UTEP)

UT Southwestern

fX

UT MD Anderson

4. Which University of Texas Participating Organizations will be engaged in this research?
Column A- Participating Organizations
Column 8 -Institutions affiliated with the participating
organization
Insert the institutions affiliated with the participating organization
Select the Participating Organization(s) that will be engaged in
the research
that will also be engaged in the research
UT at Arlington (UTA)
UT Austin (UT Austin)
UT Brownsville
UT at Dallas (UTD)
UT at El Paso (UTEP)
UT Pan American
UT Permian Basin

10

UT San Antonio (UTSA)
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UT Centralized IRB Review
Notification to Relying Organization
Intent to Submit for Centralized Review
UTTyler
UT Southwestern
UT Medical Branch (UTMB)

D

UT Health Science Center at Houston (UTHealth)
UT Health Science Center at San Antonio (UTHSCSA)
UT Health Science Center Tyler
UT MD Anderson

FOR IRB OFFICE USE ONLy

. r10n
1. Sl
e ect t he approonate 0 r amza

r--

r-

Dallas

[J

Permian Basin

Austin

EI Paso

D

UTSA

Brownsville

Pan American

Arlington

~

,..-

[J

.....-

Tyler

Southwestern

HSC San Antonio

UTMB

HSC Tyler

HSC Houston

ll::::

MD Anderson

2.

3. Notification Preference - the ReviewinCIIRB must notify this institution of approvals and study closure usinQ the followinQ method(s):
send a monthly statement of listing the protocols approved in
send a copy of the IRB letter
the previous month
.-'Send an copy of the IRB letter to the Site PI at this
send a weekly statement of listing the
organization who is then responsible to provide this
protocols approved in the previous week
infomnation to the Institution

D
D

D

w

4. Federalwide Assurance lnfomnation- select the a licable statements
The box that applies Subpart A to all research is checked
The box that applies Subparts B. C. and D to all research Is checked
5. Verificalion th9! Reviewing IRB is listed on FWA
...}Oe IRB designated in Item 3 above is listed on this institution's Federalwide Assurance
The IRB designated in Item 3 above is also listed on the Federalwide Assurance for each
affiliated institution listed in Item 4, Column B

g
i[B"

6. Signature of the Official Authorized by Organization:

\'l...- l1,...-(L...
Date

Aman U. Buzdar, M.D.

2
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Appendix C

CPHS IRB UTHSC Confirmation Letter
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UTHealth
The Univ r sity of Tex s
H~tth

TO:

Sci-.:'lc o Ccntel" a t Haur.ton

Faith Strunk
UT-H- SN - Nursing

FROM: Cynthia Edmonds, MLA
IRB Coordinator
Office of Research Support Committees
DATE: January 16, 2013
RE:

HSC-SN-12-0880
Symptoms in Early and Long-term Breast Cancer SuNivors

Reference Number: 091363
Dear Ms. Strunk,
This is a confirmation letter that the Committee for the Protection of Human Subjects
(CPHS), the Institutional Review Board at the University of Texas Health Science Center
at Houston, has received all the applicable documents for the above referenced protocol.
The CPHS agrees to rely on the reviewing IRB, MD Anderson Cancer Center, which
granted approval on November 9, 2012. It is your responsibility to maintain approval
with the MDACC lRB and renew your protocol per their schedule.
Please feel free to contact the Committee for the Protection of Human Subjects (CPHS)
at 713-500-7943 if you have any additional questions or concerns.
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Appendix D

Letter of Support
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- HE UNIVE RSITY OF TEXAS

.MDAnderson

Gancei-Center

VICente Valero. MO, FACP

Professor of Medicine. Nellie S. Connally !lre~st Center
Chairman ,\d·lnterlm. Deparunentof Breast Medical Oncology
Clinical Director. Morgan Welch Innammatory Breast Cancer
Rcsc•rch and Clinic
vvalero@mdanderson.org

Making Cancer History'
D 713·563-0755
• 713·792-2817
713-794-4385
Breast Medical Oncology -Unit 1354
1515 Holcombe Blvd , Houston, TX 77030

December 12, 2012

Faith A. Strunk, MSN, RN, FNP
The University of Texas Health Science Center School of Nursing
6901 Bertner Avenue
Houston, TX 77030
RE:

Letter of Support- Symptoms in Early and Long-term Breast Cancer Survivors Who
Have Completed Primary Therapy 2012-0909

Ms. Strunk:
This letter acknowledges your interest in conducting the above study in the Nellie B. Connelly
Breast Center at the University of Texas MD Anderson Cancer Center. I believe your study
will make valuable and important contributions, and we look forward to supporting you and
your research, which involves 132 participants from the Breast Center.
I thank you for the opportunity to work with you on this study. Our patients depend upon
exciting and quality research like this to give them hope.

Vicen e Valero, M.D., F.A.C.P.
Chairman Ad-Interim
Professor of Medicine
VV /bmc
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Appendix E

Demographic/Healt h History Form
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Demographic Form
1.

Birth date: Month_Day___Year_ _

2.

Participant's marital status
Married/Partnered D
Divorced
D
Widowed
, D

3.

Race:
Asian or Pacific Islander
Black Non-Hispanic
Native American or Alaskan
Native

(at present):
Separated
Single, living with another adult
Single, living alone

D

D
D

D
0
D

Hispanic
White Non-Hispanic
Other (Specify)

4.

Primary language spoken:_

5.

Education (Mark only the highest completed):
High School D
Associate
Bachelors 0
Masters
PhD
0
Technical School
Other_

D
D

D

D
D

0

6.

Job status (check the one that best describes your status):
Employed outside the home, fulltime
D
Unemployed
Employed outside the home, part time
D
Retired
Disabled due to illness
D
Work at home

7.

Menstrual status (check the one that best describes your status):
Premenstrual (still having periods)
0
Perimenopausal (usual pattern of periods is altered)
0
Postmenopausal (no periods for one year or more)
D

8.

Other health problems: Have you been diagnosed by a health care
provider with any chronic medical conditions? Please list them
below. If yes, has this condition limited your current daily activities?

D
0
D
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Appendix F

M.D. Anderson Symptom Inventory

Copyright 2000 The University of Texas M. D. Anderson Cancer Center
All rights reserved
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Date:--------

Institution:._ _ _ _ _ _ __

Participant Initials:-----

Hospital Chart#:._ _ _ _ __

Participant Number:----~Ol

As Bad Aa You
Can Imagine

,resent

0

1

2

3

0

:o .

4

5

6

0

0

0

·1. Your feeling sad at ~s WORST?

o:0

12. Your vomiting at its WORST?

o : o : o o : o : o:o

13. Your numbness or tingling at
its WORST?

0: 0: 0 : 0: 0 : 0 :

.

'

'

'

8

7

9

o : 0 : o:

10

0

0 : 0: 0: 0 :

o: o:_o:_ 0 :
_.

, _

0

Part II. How have your symptoms Interfered with your life?
Symptoms frequently interfere with how we feel and function. How much have your symptoms interfered with
the following items In the last 24 hours:
Old Not
Interfere

0

14. General activity?

lntelfenad
Complete~

1

2

3

o: 0

0 : 0: 0
'

15. Mood?

0: 0: 0 : 0:

16. Work (including work around
the house)?

0:

o: o:

17. Relations with other people?

o : o:

18. Walking?

o:

4

0

5

6

7

8

9

10

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

o : o:

o: o : o : 0
o: o : 0 0

o: o: o: o : o:

0

;

....- 19. Enjoyment of life?

o:

0

o:

0

o· o: c

0

0

0 0
-. - - -

c

0
-·

Copyright 2000 The University of Texas M. D. Anderson Cancer Center
All rights reserved
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Appendix G

Karnofsky Performance Scale
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KARNOFSKY PERFORMANCE SCALE

Description

100

Normal, no complaints, no evidence of disease

90

Able to carry on normal activity;minor signs or symptoms of disease

80

Normal activity with effort; some signs or symptoms of disease

70

Cares for self, unable to carry on normal activity or to do active work

60

Requires occasional assistance, but is able to care for most of
his/her needs

50

Requires considerable assistance and frequent medical care

40

Disabled, requires special care and assistance

30

Severely disabled, hospitalization indicated. Death not imminent

20

Very sick , hospitalization indicated. Death not imminent

10

Moribund, fatal processes progressing rapidly

0

Dead
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Appendix H

Charlson Comorbidity Index
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Charlson Comorbidity Index
Weight

Condition

1

Myocardial infarct
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Ulcer disease
Mid liver disease
Diabetes
Hemiplegia
Moderate or severe renal disease
Diabetes with end-organ damage
Any tumor
Leukemia
Lymphoma
Moderate or severe liver disease
Metastatic solid tumor

2

3
6

D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
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Appendix I
Subject Log
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SUBJECT LOG
ACCESSION#

PROTOCOL 2012-0909
DATE

STAGE

ENROLLED

TNM

&

RECEPTOR STATUS

TIME

TIME

IN

OUT
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Appendix J

Subject Log by Stage
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SUBJECT LOG BY STAGE
YES Adjuvant
Hormonal/Endocrine Tx
STAGE I
1)

2)

PROTOCOL 2012-0909
Early {1-3 YRS)
0-36 mos

NO Adjuvant
Hormonal/Endocrine Tx
STAGE I
1)

2)

3)

3}

4)
5)

4)
5)

6)
7)

6)

4)
8}
9)
10)

STAGE II
1)

7)
8}
9)
10)
11)
STAGE II
1)

2)

2)

3)

3)

4)
5)

4)
5)

6)

6}

7)
8)
9)

7)
8)
9)

10}
11)
STAGE Ill
1)
1)

10}
11)
STAGE Ill
1)

2)
2)

3)

3)
3)

2)
4)
5)
6)

4)
4)
5)

7)
8}
9}

6)

10)
11)

7)

EARLY (1-3 YRS)
0-36 mos
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Appendix K

Recruitment Schedule
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RECRUITMENT SCHEDULE
Appt
0800
0830
0900
0900
0930
0930
1000
1000
1030
1030
1100
1100
1130
1130
1200
1230
1300
1300
1330
1400
1400
1430
1430
1500
1500
1530
1530
1600
1600 '
1630
1630

Provider

Pt Initials

PROTOCOL 2012-0909
MRN

Stage/TNM

ER/PR/H2N

Meds

Months
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Certificate of Human Subjects Protection Training
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"

.....

MDANJERSON

CANCERCENfER
Making Can cer 1-listory"'

<GEJRT]fi<CATE Of' <COMPLETION
is liere6y granted to
Faith A. Strunk

to certify satisfactory compfetion of tlie

Iiun1a11 Subjects Protection Trainin8
011

March 04,

2009

2009
Refresher Course
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IviDAii erson

GaneeJ: Center

is liere6y g-ranted to
Faith A. Strunk

to certify satisfacto·ry compfetion oftlie

IRB Review for Non--exen1pt
Iiu111an Subject Researd1
011

June 14, 2011

'{L,~A-"
L

..,
L

V \( <.
()
Sigunnru

7'\.

J

I

a .·
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Appendix M

Permission to use the Charlson Comorbidity Index

85

-----Original Message----From: Mary E. Charlson, MD [mailto:mecharl@med.cornell.edu]
Sent: Friday, September 21, 2012 2:29 PM
To: Strunk, Faith A
Subject: RE: permission for use of Charlson Comorbidity Index
Good Afternoon,
You may use the index for your study.
Best,
Mru.:y Charlson

From : Strunk, Faith A [Faith.A.Suunk@uth.tmc.edu]
Sent: Thursday, September 20, 2012 3:23 PM
To: Mary E. Charlson, MD
Subject: permission for use of Charlson Comorbidity Index
Dear Dr. Charlson,
I am Faith Strunk, a doctoral student at the University of Texas- Houston, Health Science
Center School of N ursing. I am currendy planning a pilot study that is looking at symptoms
in breast cancer patients who have completed primary therapy (surgery,
chemotherapy/ biotherapy and radiation) and the effects of time post-therapy and adjuvant
endocrine therapy. I am also exploring the effects of functional status and comorbidities on
symptom severity and interference. Acknowledging the reliability, validity and applicability to
my study population, I am writing to request your permission to use the Charlson
Comorbidity Index in my study.
I will cite your article: Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: development and validation. J
Chronic Dis. 1987;40(5):373-83 when we publish the results.
T hank you for your time,
Faith A . Strunk
doctoral student
University of Texas- H ouston Health Science Center School of Nursing
cell: 713-382-7204
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-----Original Message----Fronn: synnptonnresearch
Sent: Tuesday, October 16, 2012 4:49PM
To: Strunk,Faith A
Cc: synnptonnresearch
Subject: RE: Order Fornn for Pain Research Group Assessnnent Tools
I have attached the MDASI-core as you requested. Please let nne know if you have any
questions. Thank you for your interest in the MDASI.
The ennail that is sent with the tool is the authorization letter for all the non-funded
acadennic research or educational purpose.
Best regards,
NazimAli
-----Original Message----Fronn: Faith Strunk [mailto: fastrunk@nndanderson.org]
Sent: Friday, October 12, 2012 1:45PM
To: synnptonnresearch
Subject: Order Form for Pain Research Group Assessment Tools

Order Fornn for Pain Research Group Synnptonn Assessnnent Tools

Assessnnent Tool: M.D. Anderson Synnptonn Inventory (core MDASI)
Psychonnetrically validated language(s): Chinese Simplified,English,Filipino,F rench, Greek,] apanese,Korean,Russian
Linguistically validated language(s):
Afrikaans,Arabic,Dutch,German,Hebrew ,Hindi,Italian,Portuguese - Brazil,Portuguese Portugal,Spanish,Swedish,Turkish,Vietnannese
Purpose: Non-funded acadennic research
Study Type: Descriptive study or survey
Detailed description:
Much of the survivorship synnptonn literature has focused on synnptonns and supportive care
during primary therapy, few studies have looked at breast cancer survivors much further
than 2 years after connpleting primary therapy, and those that have, have contradictory
results. Pain, fatigue, and sleep disturbances are nnost often found. T his study will address
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the symptoms experienced by early (less than 3 years after completion of primary therapy)
and longer term survivors (years 3-5 after completion of primary therapy) . We will assess
functional status, comorbidities and the experience of symptom burden expressed by the
survivors. We will identify and compare the symptoms experienced by early and long-term
breast cancer survivors related to the use of adjuvant endocrine therapy.
Study ID: Symptoms in early and long-term survivors of breast cancer who have completed
primary therapy
Disease Type: Invasive breast cancer, stages I-III
Mailing Address:
First Name: Faith
Last Name: Stmnk
Title:
Company: MDACC
Department: Breast Medical Oncology
Address: 1515 Holcombe Blvd Unit 1354
City: Houston
State: TX
Country: United States
ZIP Code: 77030
Telephone: 713-563-0774
Fax: 713-563-0908
E -mail: fastmnk@mdanderson.org

Billing Address: Same as Mailing Address
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Protocol Body

1.0 Background
Breast cancer is the most common cancer in women in the United States (excluding skin
cancer); one in 8 women will develop it during her lifetime (American Cancer Society,
2011). Overall women treated for breast cancer have an 89% survival rate after 5 years and
75% after 15 years. The National Cancer Institute has estimated that there were
approximately 2.7 million breast cancer survivors in the United States as of January 2009
(2011). The number of all cancer survivors is projected to grow by 3% per year (Maddams,
eta!., 2009). The breast cancer population is no exception; due to improvements in cancer
care, earlier diagnosis and treatment larger numbers of women are living longer and
cancer-free after diagnosis and treatment. Many survivors, once having completed primary
therapy (surgery, chemotherapy/biotherapy, and/or radiation) continue to have long-lasting
symptoms, single or multiple (Barsevick, 2007; Cleeland, 2007; Janz, et al., 2007; Rosedale
& Fu, 201 0). The experience of multiple symptoms has been identified as symptom burden
(Burkett & Cleeland, 2007; Gapstur, 2007; Gill, Chakraborty & Selby, 2012). Symptom
burden is defined as the subjective, quantifiable prevalence, frequency and severity of
symptoms and encompasses the patient's perception of the impact of symptoms (Cleeland,
2007; Gapstur, 2007).
The experience of symptoms in survivors has been evaluated, but much of the I iterature has
been focused on symptoms and suppmtive care during primary therapy (Chung, et al.,
2009). Some studies have concentrated on the early survivorship periods; beginning at the
end of primary therapy up until27 months alter completing primary therapy (Janz, et al.,
2007, Thompson, 2007, Park, Bae, Jung & Kim, 2011, Penttinen, et al., 2010,, Brant, et al.,
2011, Yi, Swartz and Reyes-Gibby, 2011, Ganz, Kwan, Stanton, Bower and Belin, 2011).
These studies have found symptoms related to primary therapy with an impaired quality of
life related to these reported symptoms (Janz, et al., 2007, Park, et al., 201 L Bower, 2008,
Dahl, Nesvold, Reinertsen, & fossa, 20 ll ). The symptoms most fi·equently cited in the
aforementioned studies included pain, fatigue or lack of energy, difficulty sleeping, arm
pain and lymphedema. breast symptoms, feeling irritable or nervous, menopausal
symptoms, weight changes, nausea, depression, and cognitive dysfunction. A number of
studies have focused on a specific symptom, such as pain (Mao, et al., 2009, Lundstedt, et
a!., 2012, Rief, eta!., 2011), lymphedema (Armer & Stewart, 2010, Meeske, et al., 2009,
Smoot, eta!. 20 10), fatigue (Bower, et al, 2008, Bower, eta!., 2011, Thompson, 2007) or
menopausal symptoms (Leining, et al., 2006, Loibl, Lintermans, Dieudonne, & Neven,
2011, Ruddy, eta!., 20 II). Cancer related fatigue was identified by 21% of both the 1-5
year and 5-1 0 year survivors (Bower, et a!., 2008). Sleep disturbances, fatigue and pain
persisted in Hartl eta!. 's study of survivors evaluated at an average of 4.2 years (2003).
Several studies have had contradictory findings. Castellon, et al. found that cognitive
dysfunction symptomatically abated in the 12-24 months after adjuvant chemotherapy
(2004). Jim, et al., (2009) found significant differences between women who had received
chemotherapy or radiation compared to healthy matched controls after 6 months. Tannock,
Ahles, Ganz and van Drum's 2004 review found durable cognitive effects in 9 to 75% of
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patients, although the higher percentages were seen in those evaluated in a closer time
frame with chemotherapy. However, in their study of longer term survivors (5 - 15 years),
Klein eta!. (20 11) found an improvement in all symptoms except cognitive functioning and
insomnia. The discrepancies among the findings may be related to the variability in primary
therapy over time, pre-existing comorbidities or the use of adjuvant endocrine or hormonal
therapy.
Conceptual Framework Symptom Burden

The proposed study will address the symptoms experienced by both early smvivors (less
than 3 years after completion of primary therapy) and longer term survivors (years 3-5 after
completion of primary therapy). Symptoms may be caused by comorbid illnesses or acute
injuries, related to the disease itself or may be caused by treatments, in which case they are
called side effects or toxicities (Cleeland, 2007). The framework of Symptom Burden
(Cleeland, 2007, Gapstur, 2007) is the conceptual framework chosen for this study.
Symptom burden has been described as the subjective counterpart to tumor burden
(Cleeland & Reyes-Gibby, 2002) as well as the sum ofthe severity and impact of symptoms
(Cleeland, 2007). It affects multiple patient outcomes, including survival, functional status
and quality of life. (Gapstur, 2007). Symptom burden is active, and changes over time, as
patients undergo treatment or experience exacerbations or remissions of their disease (Vig
& Pearlman, 2003 ). In this framework, symptoms related to treatment often are viewed as
compl icating post treatment recovery (Cleeland, 2007, Cleeland & Reyes-Gibby, 2002).
In this study, we will assess functional status, comorbidities and the experience of symptom
burden. This study also will explore the association of comorbidities and symptoms
expressed by early and long term survivors. The evaluation of concunent co morbidities is
wananted because as comorbidities have been related to symptom severity (Kurtz, et a!,
1999). This study will also address the associations between functional status and
symptoms related to adjuvant endocrine or hormonal therapy.
Historically, the literature has addressed the symptoms of survivors during their primary
therapy or shortly thereafter. But no studies have identified and compared the symptoms
experienced by early and long term breast cancer survivors related to the use of adjuvant
endocrine or hormonal therapy.

2.0 Objectives
Primary Objectives

1. To determine whether symptom burden differs between early survivors (less than
3 years post-primary treatment) and long-term survivors (3 to Jess than 6 years
post-treatment, inclusive).
2. To determine whether symptom burden differs between women who take
endocrine or hormonal adjuvant therapy and those who do not.
Secondary Objectives
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1. To determine, whether the effect of time post-treatment and endocrine or

hormonal adjuvant therapy has an additive effect upon symptom burden or
whether it has a synergistic or antagonistic effect upon symptom burden.
2. To determine whether symptom interference differs between early survivors and
long-term survivors and between those who do and do not take adjuvant endocrine
or hormonal therapy, as well as to determine if time post-treatment and use of
adjuvant endocrine or hotmonal therapy have an additive or interactive effect
upon symptom interference.
3. To determine if differences in individual symptom severity and interference exist
between early and long-term survivors, with and without the use of adjuvant
endocrine or hormonal therapy.
Exploratory Objective
To determine whether functional status and comorbidities affect symptom severity and
interference.

3.0 Number of Patients
We plan to enroll 33 early survivors who have not received adjuvant endocrine or hormonal
therapy, 35 early survivors who have received (or are cunently receiving) adjuvant
endocrine or hormonal therapy, 33 long-term survivors who have not received adjuvant
endocrine or hormonal therapy, and 33 long-term survivors who have received (or are
currently receiving) adjuvant endocrine or hormonal therapy. Early survivors are those who
finished primary treatment less than 3 years prior to the date of survey; long term survivors
are those who finished their primary treatment at least 3 years prior to date of survey but
less than 6 years prior to the date of survey.
We wi ll stratify the participants by stage so that 1/3 of each group will have had Stage I
cancer, 1/3 will have had Stage II cancer and 1/3 will have had Stage III cancer. We expect
that approximately 80% of breast cancer patients will have used adjuvant endocrine or
honnonal therapy, and that the pool of early-term survivors will be larger than the pool of
late-term survivors. Therefore, we will accrue each survivor type until we meet minimum
sample size requirements for the group; this means that enrollment in some groups and
strata of the study might stop before enrollment in other groups. This may lead to biased
results since not all women will be enrolled from the same time cohort, however, this is a
pilot study to be used to plan a longitudinal study and therefore these results will be for
hypothesis generation when planning a future study.

4.0 Patient Eligibility
Inclusion criteria:
Study participants must:
I. Be a woman 18 years of age or older.
2. Be a survivor with a diagnosis of invasive breast cancer who has no clinical
evidence of disease.
3. Have completed primary therapy (surgery, chemotherapy/biotherapy, and
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radiation) less than six years prior to study entry. She may continue to receive
adjuvant endocrine or hormonal therapy including tamoxifen, toremifene,
anastrazole, exemestane or letrozole.
4. May be non-English speaking.
Exclusion criteria:
1. Study participants may not be diagnosed with noninvasive, metastatic,
inflammatory, or recutTent breast cancer.
2. Participants may not be receiving chemotherapy or biotherapy at time of
enrollment.
3. Lack of approval of each participant's physician. Physician' s will be approached
by the investigator and asked if they feel the participant meets entry criteria prior
to the subjects being approached for consideration of enrollment.
4. Pregnant women will be excluded.

5.0 Instruments
MDASI-The MDASI will be used to measure symptom severity, interference and burden.
The MDASI is a 19-item self-report measure of the severity and impact of cancer-related
symptoms (Cleeland et al, 2000). Respondents are asked to rate the severity of
cancer-related symptoms (13 items) and their interference (6 items) with individual
functioning. The global symptom severity and global interference scores measure the
patient's symptom burden. Validity has been tested using principle factor analysis with
oblique rotation; reliability established with alphas ranging from 0.82-0.85 for the symptom
items and 0.91 for the interference scale (Cleeland, et al., 2000). The MDASI is available
in multiple languages.
The Karnofsky Performance Status (KPS)-The KPS will be used to measure functional
status. The KPS is a clinician or investigator completed scale that classifies patients based
on their degree of functional impairment on a scale from 0(dead) to 1OO(normal, no
complaints, no evidence of disease). (Schag, Heinrich and Ganz, 1984). It is further
subgrouped into three groups: A. Able to carry on normal activity and to work, no special
care needed, B. unable to work, able to live at home and care for most personal needs,
varying amount of assistance needed and C. Unable to care for self, requires equivalent of
institutional or hospital care; disease may be progressing rapidly. The KPS has shown
reliability and validity previously with Cronbach's alpha of 0.97 and construct validity
demonstrated with a p<O.OOl(Mor, Laliberte, Monis & Wiemann, 1984, Schag et al.,
1984).

94
Protocol 2012-0909
April19, 2013
Page 6

The Charlson Comorbidity Index (CCI) - The CCI will measure comorbidities. The CCI
is an investigator completed index that measures 17 clinical conditions that are weighted to
assess the effect of the conditions on the patient's prognosis. Item scores range from 1 to 6
for each item and are based on the relative risk for each. Scores range from 0 to 34, with
higher scores signifying greater comorbidity. An adjustment will be made to address all
patiicipants beginning with a score of2, given because they all have cancer. It has
established reliability with clinical conditions, including cancer (Hallet al., 2004).

6.0 Data Collection Procedures
Enrollment: The investigator will check with the Nellie B. Connelly Breast c.enter
appointment desk for eligible patients based on inclusion criteria. Physicians will be
contacted for permission to approach the patient.
Data Collection Procedures:
1. Review Breast Center appointment schedule for sunrivors less than 3 years after
completion of primary therapy and those from 3 -5 years.
2. Check with primary attending oncologist to ask if it would be permissible to
approach the patients to seek their participation in a study on symptom
assessment.
3. Once the patient is in a clinic exam room, knock on the door, introduce self as a
researcher and ask if this is a good time to speak with the patient.
4.

Explain the purpose of the study. The participant will complete a symptom instrument and
either the participant or the investigator will complete the demographic history form. The
expected time frame for completion is no more than 10-15 minutes. Ask if there any
questions.

5. Once all questions have been addressed to the patient's satisfaction, ask ifthey
would agree to participate in the study.
6. Provide the consent and wait for the signature before proceeding.
7. Provide a copy of the demographic history form to the patient and ask them to
complete it or the investigator will complete it.
8. The investigator will determine the functional status of the patient (Karnofsky
score); gather information from the medical record to complete the Charlson
Co-morbidity Index.
9. Provide a copy of the MDASI to the patient and explain the scoring.
I 0. If the patient wishes to stop before completing the instrument, thank them for their
time and exit the room.
11. Ask the patient if they have any symptoms not listed on the MDASI to list them
on the bottom of the MDASI.
12. Note the time the instrument was started and time completed.
13. Before placing the completed instruments in a plain unmarked envelope, review to
check for missing data. If any data are missing, the investigator will review with
the patient for an error in completing the instrument or a comprehension issue.
14. Each envelope containing completed instruments and consents will be kept in a
locked cabinet, entered into Core and assigned a study number. Each patient will
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be assigned a study number.
15. If the patient expresses distress, or rates any symptom 7 or higher, the researcher
will contact their treating physician. The patient will also be instructed to contact
their health care team.

7.0 Evaluation During Study
The primary researcher will track time from primary treatment and receipt of endocrine or
honnonal therapy to ensure equitable distribution of participant populations. Descriptive
data will be reviewed weekly to assess adequate representation of time since completion of
primary therapy. The researcher will track estrogen or progesterone receptor status, as it
may not be equitably distributed across different disease stages, in order to maintain a
sample representative of each group.

8.0 Data Monitoring Plan
The investigator and dissertation chair will meet weekly to review progress. The primary
investigator will review weekly to ensure adequate representation across stages and
estrogen receptor status. Other committee members may attend as desired. All portions of
the study being conducted, including any missing data, enrollment of subjects, adverse
effects, data collection and protection strategies will be reviewed. This study is minimal
risk, so study related adverse effects are not expected. Should any adverse effects occur,
they will be investigated, logged, and reported to both the MD Anderson Cancer Center's
IRB and the University of Texas Health Science Center (CPHS) within 48 hours of
occurrence. This study is expected to be completed within one year. Progress of the study, a
completed report, adverse event logs, certification oftraining requirements, HIPPA fonns,
and publications resulting from this study will be sent to the IRB and CPHS at the
completion of the study and during any audits.

9.0 Protocol Monitoring Plan
Security Plan: Paper instruments will be coded and de-identified. The code list will be

kept in the PI's office in a locked cabinet and not shared. All completed instruments will
be placed in a brown envelope upon completion and stored in a locked file with no
identifiers. Once the information is transferred into the computer, the file will be
password protected. Once the study is completed, all paper data including the code list
will be shredded.
Distress Plan: If the patient expresses distress, or rates any symptom 7 or higher, the
researcher will contact their treating physician. The patient will also be instructed to
contact their health care team.
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10.0 Statistics
Using a 2x2 factorial design, we will have 80% power to detect a one-unit difference in
mean symptom burden scores by use of adjuvant endocrine or hormonal therapy, which
translates to a standard deviation among means of0.5. Additionally, we have over 95%
power to detect a 2-unit difference between early-term and long-term survivors, which is
the same as a I .0 standard deviation among means, and to detect a 1.12 standard deviation
among means for the interaction effect. All testing will be 2-sided using a 5% level of
statistical significance. A subject standard deviation of2.0 was used to calculate power,
based upon findings by Cleeland, et. al. (2000). Because we have two primary objectives,
we will have a 10% chance of falsely rejecting at least one of our primary hypotheses.
Descriptive statistics will be used to assess the distributional characteristics and
demographics of the study sample. Summary statistics and graphs will be used to examine
symptom burden, as well as individual symptom severity and interference. Fisher's exact
tests and t-tests will be used to determine whether demographic and clinical baseline data
are similar between short- and long-term survivors, as well as between those who had
adjuvant endocrine or hormonal therapy and those who did not. Symptom burden and
interference will be calculated separately, as recommended by the MDASI User Guide. We
will use 2-way ANOV A models to evaluate differences in symptom burden, symptom
interference and severity/interference of individual symptoms. Finally, we will add
Karnofsky Performance Status and the Charlson Comorbidity Index to our models to
evaluate impact of functional status and comorbidities upon symptoms. All models will
contain terms for stage of disease to account for stratification on that factor, as well as a
term for age to adjust for the effects of age upon symptom severity and interference.
Anticipated Problems and Alternate Strategies
Missing data: A single investigator will be collecting the data. The completed forms will

be reviewed when collected. Any missing data will be discussed to ascertain an error in
completing the instrument or a comprehension difficulty with an item. Percent of missing
items will be calculated and is expected to be less than 1%. The MDASI User's Guide
allows for calculation of severity and interference scores when not all items are answered.
Its recommendations will be implemented when not all 19 items are answered.
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INFORMED CONSENT/AUTHORIZATION FOR PARTICIPATION IN
RESEARCH
Symptoms in Early and Long-term Breast Cancer Survivors Who Have
Completed Primary Therapy
2012-0909
Subtitle:

Study Chair: Faith A. Strunk

1.
Medical Record Number

Participant's Name

You are being asked to take part in this psychosocial research study at The
University of Texas MD Anderson Cancer Center ("MD Anderson"). This consent
form explains why this research study is being done and what your role will be if you
choose to take part. This form also describes the possible risks connected with
being in this study. After reviewing this information with the person responsible for
your enrollment, you should know enough to be able to make an informed decision
on whether you want to take part in the study.
You are being asked to take part in this study because you are a woman who has
been treated for breast cancer and are receiving follow up care.

DESCRIPTION OF RESEARCH

2. PURPOSE OF STUDY

The goal of this research study is to learn what symptoms breast cancer survivors
may be having after completing primary therapy (surgery, chemotherapy or
biotherapy, and/or radiation). Researchers also want to learn how taking tamoxifen,
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anastrazole, letrozole, or exemestane impacts the activities of daily living, time after
primary therapy, and chronic illnesses.

3. DESCRIPTION OF STUDY
If you agree to take part in the study, you will complete a questionnaire about any
symptoms you may be having after primary therapy. You will also complete a
questionnaire that asks about your background such as age, employment, and any
chronic illnesses that you may have.
The questionnaires should take a total of about 20 minutes to complete. If your
questionnaires suggest that you are depressed, upset, or distressed, the researcher
will let your clinic team know.
Length of Study
Your participation in this study will be over after you complete the second
questionnaire.
This is an investigational study. There will be no cost to you for participating in
this study.
Up to 135 participants will be enrolled in this study. All will take part at MD
Anderson.

4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS
You should discuss the risks of questionnaires with the study chair. The known
risks are listed in this form , but they will vary from person to person. Some
questions may make you feel upset or uncomfortable. You may refuse to answer
any question. If you have concerns after completing the questionnaires, you are
encouraged to contact the study researchers or staff.
Although every effort will be made to keep study data safe, there is a chance that
your personal health information could be lost or stolen. All study data be stored in
password-protected computers and/or locked file cabinets. There will be no
personal identifying information connected to your questionnaire answers. The
study data will be destroyed 5 years after the study has been published.
Researchers will take appropriate steps to keep your information private. However,
there is no guarantee of absolute privacy.
This study may involve unpredictable risks to the participants.
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5. POTENTIAL BENEFITS

Future patients may benefit from what is learned. There are no benefits for you in
this study.

6. ALTERNATE PROCEDURES OR TREATMENTS

You may choose not to take part in this study. You may seek help for any
symptoms you may be having outside of this study by seeing your doctor.
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Additional Information

7. You may ask the study chair any questions you have about this study. You may
contact the study chair, Faith A. Strunk, at 713-563-0774. You may also contact
the Chair of MD Anderson's Institutional Review Board (IRB - a committee that
reviews research studies) at 713-792-2933 with any questions that have to do with
this study or your rights as a study participant.
8.

Your participation in this research study is strictly voluntary. You may choose not to
take part in this study without any penalty or loss of benefits to which you are
otherwise entitled. You may also withdraw from participation in this study at any
time without any penalty or loss of benefits. If you withdraw from the study, data
collected about you up to the time you withdrew may have to remain in the study
database for inclusion in the data analysis. If you decide you want to stop taking
part in the study, it is recommended for your safety that you first talk to your doctor.
If you withdraw from this study, you can still choose to be treated at MD Anderson.

9.

This study or your participation in it may be changed or stopped at any time by the
study chair or the IRB of MD Anderson.

10. You will be informed of any new findings that might affect your willingness to
continue taking part in the study.
11. MD Anderson will take appropriate steps to keep your personal health information
private. However, there is no guarantee of absolute privacy. Health authorities,
and the IRB of MD Anderson might review your record to collect data or to check
that the research is being done safely and correctly. In some situations, health
authorities could be required to reveal the names of participants.
12. MD Anderson may benefit from your participation and/or what is learned in this
study.
STUDY COSTS AND COMPENSATION
If you suffer injury as a direct result of taking part in this study, MD Anderson health
providers will provide medical care. However, this medical care will be billed to your
insurance provider or you in the ordinary manner. You will not be reimbursed for
expenses or compensated financially by MD Anderson for this injury. You may also
contact the Chair of MD Anderson's IRB at 713-792-2933 with questions about
study-related injuries. By signing this consent form, you are not giving up any of your
legal rights.
Unless otherwise stated in this consent form, all of the costs linked with this study,
which are not covered by other payers (health maintenance organization [HMO],
health insurance company, etc.), will be your responsibility.
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There are no plans to compensate you for any patents or discoveries that may result
from your participation in this research .
You will receive no compensation for taking part in this study.
Authorization for Use and Disclosure of Protected Health Information:

A. During the course of this study, the research team at MD Anderson will be
collecting information about you that they may share with the parties named in
Section E below.

B. If you refuse to provide authorization to disclose your protected health
information, you will not be able to participate in this research study.
C. Your protected health information will be protected according to state and federal
law. However, there is no guarantee that your information will remain
confidential, and it may be re-disclosed at some point.
D. All identifying information such as your name and address will be kept private.
This information may be kept at MD Anderson forever. You will be assigned a
code number so that your name will not be used. The research team at MD
Anderson will be able to link the code number to your name. In some instances,
in order to ensure the scientific value of the study, the parties named in Section
E below will be able to view your study record but will not be permitted to copy
any identifying information contained in your record.
E. The following parties may view your identifying information:
•
•
•
•
•
•

Officials of the doctoral nursing program at the University of Texas -Houston
Health Science Center School of Nursing
The Office for Human Research Protections (OHRP) (a regulatory agency
that oversees research in humans)
The IRB of MD Anderson
Officials of MD Anderson
Study monitors who verify the accuracy of the information
Individuals who put all the study information together in report form

F. You have the right to see and reproduce your records related to the research study,
and ask for corrections, for as long as this information is held by the study chair
and/or MD Anderson. However, in some studies, in order to ensure the scientific
value of the study, participants are not able to view or reproduce their study records
until the research has been completed with all participants in the study.
G. There is no expiration date for the use of your information as stated in this
authorization. You may withdraw your authorization to share your protected health
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information at any time in writing. Instructions on how to do this can be found in the
MD Anderson Notice of Privacy Practices (NPP). You may contact the IRB Staff at
713-792-2933 with questions about how to find the NPP. If you withdraw your
authorization, you will be removed from the study, and the study chair and staff will
no longer use or disclose your protected health information in connection with this
study, unless the study chair or staff needs to use or disclose some of your
research-related personal health information to preserve the scientific value of the
study. The parties listed in Section E above may use any study data that were
collected before you canceled your authorization.

H. A description of this clinical trial will be available on http://www.CiinicaiTrials.gov,
as ·required by U.S. Law. This Web site will not include information that can
identify you. At most, the Web site will include a summary of the results. You
can search this Web site at any time.
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CONSENT/AUTHORIZATION
I understand the study. I have had a chance to read the consent form for this study, or
have had it read to me. I have had a chance to think about it, ask questions, and talk
about it with others as needed. I give the study chair permission to enroll me on this
study. By signing this consent form, I am not giving up any of my legal rights. I will be
given a signed copy of this consent document.

SIGNATURE OF PARTICIPANT

DATE

LEGALLY AUTHORIZED REPRESENTATIVE {LAR)
The following signature line should only be filled out when the participant consents to
take part in the study but does not have the capacity to legally sign this document on
his or her own behalf.

SIGNATURE OF LAR

DATE

WITNESS TO CONSENT
I was present during the explanation of the research to be performed under Protocol
2012-0909.

SIGNATURE OF WITNESS TO THE VERBAL CONSENT PRESENTATION
(OTHER THAN PHYSICIAN OR STUDY CHAIR)

DATE

A witness signature is only required for vulnerable adult participants. If witnessing the assent of a pediatric
participant, leave this line blank and sign on the witness to assent page instead.

PERSON OBTAINING CONSENT
I have discussed this psychosocial research study with the participant and/or his or her
authorized representative, using language that is understandable and appropriate. I
believe that I have fully informed this participant of the nature of this study and its
possible benefits and risks and that the participant understood this explanation.

SIGNATURE OF STUDY CHAIR
OR PERSON AUTHORIZED TO OBTAIN CONSENT
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TRANSLATOR
I have translated the above informed consent as written (without additions or
subtractions) into
and assisted the people
(Name of Language)
obtaining and providing consent by translating all questions and responses during
the consent process for this participant.

NAME OF TRANSLATOR

0

SIGNATURE OF TRANSLATOR

DATE

Please check here if the translator was a member of the research team . (If
checked , a witness , other than the translator, must sign the witness line below.)

SIGNATURE OF WITNESS TO THE VERBAL TRANSLATION
(OTHER THAN TRANSLATOR, PARENT/GUARDIAN, OR STUDY CHAIR)
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EDUCATION
PhD student

University of Texas Health Science Center
At Houston
School of Nursing
6901 Bertner Avenue
Houston, TX 77030

8/2010-present

University of North Carolina
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Chapel Hill, NC 27599-2100

12/ 30/ 1993

BS, Comp Studies: Info Sys Mgmt

University of Maryland-European Division
University Blvd at Adelphi Road
College Park, MD 20742

1/30/1987

BSN

Arizona State University
PO Box 870312
Tempe, AZ 85287-0312

5/18/ 1979

State
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MSN

LICENSURE & CERTIFICATION
RN No.

RN, Family Nurse Practitioner 650215 Texas

10/31/2015

Certificate

Certifying Body
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Family Nurse Practitioner

American Nurses Credentialing Center

12/1/200911/30/2014

Advanced Oncology Certified Nurse
Practitioner

Oncology Nursing Certification Corporation

12/1/201112/31/2015

PROFESSIONAL EXPERIENCE
Institution

Position title

Inclusive Dates

Various military hospitals

Clinical Staff Nurse

5/1980-6/ 1989

Acute Minor Illness Clinic, Ft. Myer,
VA

Head Nurse

6/1989-7/1991

Family Practice Department, Ft. Polk,
LA

Family Nurse Practitioner

2/ 1993-6/1996
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1151h Field Hospital, Ft. Polk, LA

Assistant Chief Nurse

McNeese State University, Lake
Charles, LA
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11/1993- 6/1996
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9/1996-3/ 1999
Rural Health Clinic, LaGrange, GA
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Educator
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Midlevel provider (Family Nurse Practitioner)
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Family Nurse Practitioner
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Advanced Practice Nurse

9/2002-5/2004
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INTERNATIONAL EXPERIENCE
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International
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National
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05/11 -- Breast Cancer, Faculty Training Program, Nurse Oncology Education Program, Houston, Texas
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Professional Development & Education, M. D. Anderson Cancer Center; Houston, Texas
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Chair-elect
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Chair-elect
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